| Publication Information (EuropePMC) | |
| Title | Cancer PRSweb: An Online Repository with Polygenic Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent Biobanks. |
| PubMed ID | 32991828(Europe PMC) |
| doi | 10.1016/j.ajhg.2020.08.025 |
| Publication Date | Sept. 28, 2020 |
| Journal | Am J Hum Genet |
| Author(s) | Fritsche LG, Patil S, Beesley LJ, VandeHaar P, Salvatore M, Ma Y, Peng RB, Taliun D, Zhou X, Mukherjee B. |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/PGS000498.txt.gz | |
| PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,546 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/PGS000536.txt.gz | |
| PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 45 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000593/ScoringFiles/PGS000593.txt.gz | |
| PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000602/ScoringFiles/PGS000602.txt.gz | |
| PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000633/ScoringFiles/PGS000633.txt.gz | |
| PGS000559 (PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000559/ScoringFiles/PGS000559.txt.gz | |
| PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000401/ScoringFiles/PGS000401.txt.gz | |
| PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000489/ScoringFiles/PGS000489.txt.gz | |
| PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000630/ScoringFiles/PGS000630.txt.gz | |
| PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000634/ScoringFiles/PGS000634.txt.gz | |
| PGS000376 (PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000376/ScoringFiles/PGS000376.txt.gz | |
| PGS000429 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000429/ScoringFiles/PGS000429.txt.gz | |
| PGS000467 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000467/ScoringFiles/PGS000467.txt.gz | |
| PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000477/ScoringFiles/PGS000477.txt.gz | |
| PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000595/ScoringFiles/PGS000595.txt.gz | |
| PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000596/ScoringFiles/PGS000596.txt.gz | |
| PGS000385 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Pancreatic cancer | pancreatic carcinoma | 17 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000385/ScoringFiles/PGS000385.txt.gz | |
| PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000450/ScoringFiles/PGS000450.txt.gz | |
| PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000480/ScoringFiles/PGS000480.txt.gz | |
| PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 84 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000515/ScoringFiles/PGS000515.txt.gz | |
| PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,435 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/PGS000520.txt.gz | |
| PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/PGS000526.txt.gz | |
| PGS000370 (PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 87 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000370/ScoringFiles/PGS000370.txt.gz | |
| PGS000374 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000374/ScoringFiles/PGS000374.txt.gz | |
| PGS000427 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000427/ScoringFiles/PGS000427.txt.gz | |
| PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 467 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000439/ScoringFiles/PGS000439.txt.gz | |
| PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 72 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000447/ScoringFiles/PGS000447.txt.gz | |
| PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000455/ScoringFiles/PGS000455.txt.gz | |
| PGS000464 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000464/ScoringFiles/PGS000464.txt.gz | |
| PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 25 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000484/ScoringFiles/PGS000484.txt.gz | |
| PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000499/ScoringFiles/PGS000499.txt.gz | |
| PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 747 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/PGS000502.txt.gz | |
| PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 85 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/PGS000538.txt.gz | |
| PGS000546 (PRSWEB_PHECODE184.11_Phelan-ENOC_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,115,189 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000546/ScoringFiles/PGS000546.txt.gz | |
| PGS000606 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of kidney, except pelvis | kidney cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000606/ScoringFiles/PGS000606.txt.gz | |
| PGS000624 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000624/ScoringFiles/PGS000624.txt.gz | |
| PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000627/ScoringFiles/PGS000627.txt.gz | |
| PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000629/ScoringFiles/PGS000629.txt.gz | |
| PGS000654 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000654/ScoringFiles/PGS000654.txt.gz | |
| PGS000625 (PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000625/ScoringFiles/PGS000625.txt.gz | |
| PGS000649 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000649/ScoringFiles/PGS000649.txt.gz | |
| PGS000650 (PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000650/ScoringFiles/PGS000650.txt.gz | |
| PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000476/ScoringFiles/PGS000476.txt.gz | |
| PGS000381 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000381/ScoringFiles/PGS000381.txt.gz | |
| PGS000384 (PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of rectum, rectosigmoid junction, and anus | rectum cancer, rectosigmoid junction neoplasm |
1,104,018 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000384/ScoringFiles/PGS000384.txt.gz | |
| PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 389 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000402/ScoringFiles/PGS000402.txt.gz | |
| PGS000414 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000414/ScoringFiles/PGS000414.txt.gz | |
| PGS000417 (PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 1,109,519 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000417/ScoringFiles/PGS000417.txt.gz | |
| PGS000421 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000421/ScoringFiles/PGS000421.txt.gz | |
| PGS000425 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000425/ScoringFiles/PGS000425.txt.gz | |
| PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000469/ScoringFiles/PGS000469.txt.gz | |
| PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000470/ScoringFiles/PGS000470.txt.gz | |
| PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 217 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000493/ScoringFiles/PGS000493.txt.gz | |
| PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/PGS000522.txt.gz | |
| PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000525/ScoringFiles/PGS000525.txt.gz | |
| PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 310 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000529/ScoringFiles/PGS000529.txt.gz | |
| PGS000551 (PRSWEB_PHECODE184.11_Phelan-IEOC_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000551/ScoringFiles/PGS000551.txt.gz | |
| PGS000561 (PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,114,056 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000561/ScoringFiles/PGS000561.txt.gz | |
| PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000599/ScoringFiles/PGS000599.txt.gz | |
| PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000614/ScoringFiles/PGS000614.txt.gz | |
| PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000626/ScoringFiles/PGS000626.txt.gz | |
| PGS000652 (PRSWEB_PHECODE204.4_C90_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000652/ScoringFiles/PGS000652.txt.gz | |
| PGS000562 (PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,115,189 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000562/ScoringFiles/PGS000562.txt.gz | |
| PGS000638 (PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Hodgkin's disease | Hodgkins lymphoma | 16 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000638/ScoringFiles/PGS000638.txt.gz | |
| PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 63 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000437/ScoringFiles/PGS000437.txt.gz | |
| PGS000642 (PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Non-Hodgkin's lymphoma | non-Hodgkins lymphoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000642/ScoringFiles/PGS000642.txt.gz | |
| PGS000386 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Pancreatic cancer | pancreatic carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000386/ScoringFiles/PGS000386.txt.gz | |
| PGS000391 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000391/ScoringFiles/PGS000391.txt.gz | |
| PGS000420 (PRSWEB_PHECODE172.1_D03_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 147 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000420/ScoringFiles/PGS000420.txt.gz | |
| PGS000428 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000428/ScoringFiles/PGS000428.txt.gz | |
| PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000459/ScoringFiles/PGS000459.txt.gz | |
| PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 120 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000478/ScoringFiles/PGS000478.txt.gz | |
| PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/PGS000500.txt.gz | |
| PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/PGS000506.txt.gz | |
| PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,237 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000514/ScoringFiles/PGS000514.txt.gz | |
| PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000517/ScoringFiles/PGS000517.txt.gz | |
| PGS000550 (PRSWEB_PHECODE184.11_Phelan-IEOC_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,115,189 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000550/ScoringFiles/PGS000550.txt.gz | |
| PGS000557 (PRSWEB_PHECODE184.11_Phelan-OCCC_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,115,187 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000557/ScoringFiles/PGS000557.txt.gz | |
| PGS000372 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000372/ScoringFiles/PGS000372.txt.gz | |
| PGS000380 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000380/ScoringFiles/PGS000380.txt.gz | |
| PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 2,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000451/ScoringFiles/PGS000451.txt.gz | |
| PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000471/ScoringFiles/PGS000471.txt.gz | |
| PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 68 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000474/ScoringFiles/PGS000474.txt.gz | |
| PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000482/ScoringFiles/PGS000482.txt.gz | |
| PGS000555 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000555/ScoringFiles/PGS000555.txt.gz | |
| PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000632/ScoringFiles/PGS000632.txt.gz | |
| PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,356 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000539/ScoringFiles/PGS000539.txt.gz | |
| PGS000552 (PRSWEB_PHECODE184.11_Phelan-IEOC_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 41,269 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000552/ScoringFiles/PGS000552.txt.gz | |
| PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 178,259 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz | |
| PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 954 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000636/ScoringFiles/PGS000636.txt.gz | |
| PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,866 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000495/ScoringFiles/PGS000495.txt.gz | |
| PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 286,144 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/PGS000512.txt.gz | |
| PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 98,026 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000531/ScoringFiles/PGS000531.txt.gz | |
| PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 7,118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/PGS000540.txt.gz | |
| PGS000548 (PRSWEB_PHECODE184.11_Phelan-EPOC_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,441 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000548/ScoringFiles/PGS000548.txt.gz | |
| PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 148,560 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/PGS000504.txt.gz | |
| PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 12,277 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/PGS000532.txt.gz | |
| PGS000556 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 486,841 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000556/ScoringFiles/PGS000556.txt.gz | |
| PGS000558 (PRSWEB_PHECODE184.11_Phelan-OCCC_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,098,236 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000558/ScoringFiles/PGS000558.txt.gz | |
| PGS000564 (PRSWEB_PHECODE184.11_Phelan-SIOC_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 110,710 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000564/ScoringFiles/PGS000564.txt.gz | |
| PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,401 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz | |
| PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,809 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz | |
| PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 905 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz | |
| PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 771 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000597/ScoringFiles/PGS000597.txt.gz | |
| PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 656 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000628/ScoringFiles/PGS000628.txt.gz | |
| PGS000368 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 74 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000368/ScoringFiles/PGS000368.txt.gz | |
| PGS000360 (PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 25,920 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000360/ScoringFiles/PGS000360.txt.gz | |
| PGS000364 (PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 2,001 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000364/ScoringFiles/PGS000364.txt.gz | |
| PGS000375 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 370 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000375/ScoringFiles/PGS000375.txt.gz | |
| PGS000377 (PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 5,740,814 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000377/ScoringFiles/PGS000377.txt.gz | |
| PGS000379 (PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 5,715,093 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000379/ScoringFiles/PGS000379.txt.gz | |
| PGS000382 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 150 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000382/ScoringFiles/PGS000382.txt.gz | |
| PGS000394 (PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,110,438 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000394/ScoringFiles/PGS000394.txt.gz | |
| PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 3,166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000407/ScoringFiles/PGS000407.txt.gz | |
| PGS000409 (PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000409/ScoringFiles/PGS000409.txt.gz | |
| PGS000418 (PRSWEB_PHECODE172.1_C43_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000418/ScoringFiles/PGS000418.txt.gz | |
| PGS000424 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000424/ScoringFiles/PGS000424.txt.gz | |
| PGS000426 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000426/ScoringFiles/PGS000426.txt.gz | |
| PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000454/ScoringFiles/PGS000454.txt.gz | |
| PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000457/ScoringFiles/PGS000457.txt.gz | |
| PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000458/ScoringFiles/PGS000458.txt.gz | |
| PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000473/ScoringFiles/PGS000473.txt.gz | |
| PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 4,047 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000483/ScoringFiles/PGS000483.txt.gz | |
| PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/PGS000486.txt.gz | |
| PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/PGS000490.txt.gz | |
| PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000491/ScoringFiles/PGS000491.txt.gz | |
| PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 3,038 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000509/ScoringFiles/PGS000509.txt.gz | |
| PGS000542 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of uterus | uterine cancer | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000542/ScoringFiles/PGS000542.txt.gz | |
| PGS000549 (PRSWEB_PHECODE184.11_Phelan-IEOC_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 16 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000549/ScoringFiles/PGS000549.txt.gz | |
| PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz | |
| PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz | |
| PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000603/ScoringFiles/PGS000603.txt.gz | |
| PGS000605 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of kidney, except pelvis | kidney cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000605/ScoringFiles/PGS000605.txt.gz | |
| PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000631/ScoringFiles/PGS000631.txt.gz | |
| PGS000637 (PRSWEB_PHECODE201_20001-1052_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Hodgkin's disease | Hodgkins lymphoma | 1,047,511 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000637/ScoringFiles/PGS000637.txt.gz | |
| PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000404/ScoringFiles/PGS000404.txt.gz | |
| PGS000355 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000355/ScoringFiles/PGS000355.txt.gz | |
| PGS000361 (PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 87,893 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000361/ScoringFiles/PGS000361.txt.gz | |
| PGS000367 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 74 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000367/ScoringFiles/PGS000367.txt.gz | |
| PGS000389 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000389/ScoringFiles/PGS000389.txt.gz | |
| PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,103,220 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000398/ScoringFiles/PGS000398.txt.gz | |
| PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000399/ScoringFiles/PGS000399.txt.gz | |
| PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 16,316 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000403/ScoringFiles/PGS000403.txt.gz | |
| PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000405/ScoringFiles/PGS000405.txt.gz | |
| PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 292 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000406/ScoringFiles/PGS000406.txt.gz | |
| PGS000408 (PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000408/ScoringFiles/PGS000408.txt.gz | |
| PGS000412 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 16 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000412/ScoringFiles/PGS000412.txt.gz | |
| PGS000415 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 505 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000415/ScoringFiles/PGS000415.txt.gz | |
| PGS000419 (PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000419/ScoringFiles/PGS000419.txt.gz | |
| PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,073,162 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000449/ScoringFiles/PGS000449.txt.gz | |
| PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000452/ScoringFiles/PGS000452.txt.gz | |
| PGS000462 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000462/ScoringFiles/PGS000462.txt.gz | |
| PGS000465 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000465/ScoringFiles/PGS000465.txt.gz | |
| PGS000468 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000468/ScoringFiles/PGS000468.txt.gz | |
| PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 30,041 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000475/ScoringFiles/PGS000475.txt.gz | |
| PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000481/ScoringFiles/PGS000481.txt.gz | |
| PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41,744 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/PGS000496.txt.gz | |
| PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000497/ScoringFiles/PGS000497.txt.gz | |
| PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000507/ScoringFiles/PGS000507.txt.gz | |
| PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/PGS000534.txt.gz | |
| PGS000541 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of uterus | uterine cancer | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000541/ScoringFiles/PGS000541.txt.gz | |
| PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz | |
| PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz | |
| PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,311 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz | |
| PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,120,596 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz | |
| PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,023 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz | |
| PGS000644 (PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Nodular lymphoma | follicular lymphoma | 2,209,179 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000644/ScoringFiles/PGS000644.txt.gz | |
| PGS000621 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000621/ScoringFiles/PGS000621.txt.gz | |
| PGS000653 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Multiple myeloma | multiple myeloma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000653/ScoringFiles/PGS000653.txt.gz | |
| PGS000388 (PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,109,069 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000388/ScoringFiles/PGS000388.txt.gz | |
| PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000610/ScoringFiles/PGS000610.txt.gz | |
| PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000611/ScoringFiles/PGS000611.txt.gz | |
| PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000612/ScoringFiles/PGS000612.txt.gz | |
| PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000613/ScoringFiles/PGS000613.txt.gz | |
| PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 106 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000615/ScoringFiles/PGS000615.txt.gz | |
| PGS000620 (PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 522 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000620/ScoringFiles/PGS000620.txt.gz | |
| PGS000622 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000622/ScoringFiles/PGS000622.txt.gz | |
| PGS000392 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000392/ScoringFiles/PGS000392.txt.gz | |
| PGS000393 (PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,110,438 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000393/ScoringFiles/PGS000393.txt.gz | |
| PGS000395 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000395/ScoringFiles/PGS000395.txt.gz | |
| PGS000396 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
75 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000396/ScoringFiles/PGS000396.txt.gz | |
| PGS000397 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
46,920 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000397/ScoringFiles/PGS000397.txt.gz | |
| PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz | |
| PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,494 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz | |
| PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 78 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz | |
| PGS000623 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain cancer | brain cancer | 11 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000623/ScoringFiles/PGS000623.txt.gz | |
| PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz | |
| PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 47 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz | |
| PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 122 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz | |
| PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz | |
| PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz | |
| PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,301 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz | |
| PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 26,418 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz | |
| PGS000617 (PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Ocular cancer | ocular cancer | 834,009 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000617/ScoringFiles/PGS000617.txt.gz | |
| PGS000648 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 44 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000648/ScoringFiles/PGS000648.txt.gz | |
| PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 77 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000441/ScoringFiles/PGS000441.txt.gz | |
| PGS000371 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000371/ScoringFiles/PGS000371.txt.gz | |
| PGS000354 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 1,118,667 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000354/ScoringFiles/PGS000354.txt.gz | |
| PGS000357 (PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Oral cavity cancer | oral cavity cancer | 45 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000357/ScoringFiles/PGS000357.txt.gz | |
| PGS000359 (PRSWEB_PHECODE145.2_C3-TONGUENAS_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Tongue cancer | tongue neoplasm | 931,954 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000359/ScoringFiles/PGS000359.txt.gz | |
| PGS000362 (PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Laryngeal cancer | Malignant Laryngeal Neoplasm | 53 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000362/ScoringFiles/PGS000362.txt.gz | |
| PGS000363 (PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,081,646 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000363/ScoringFiles/PGS000363.txt.gz | |
| PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000400/ScoringFiles/PGS000400.txt.gz | |
| PGS000410 (PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000410/ScoringFiles/PGS000410.txt.gz | |
| PGS000411 (PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 185 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000411/ScoringFiles/PGS000411.txt.gz | |
| PGS000422 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 18 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000422/ScoringFiles/PGS000422.txt.gz | |
| PGS000423 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 29 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000423/ScoringFiles/PGS000423.txt.gz | |
| PGS000432 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 296 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000432/ScoringFiles/PGS000432.txt.gz | |
| PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 108 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000433/ScoringFiles/PGS000433.txt.gz | |
| PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 446 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000435/ScoringFiles/PGS000435.txt.gz | |
| PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 16,626 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000436/ScoringFiles/PGS000436.txt.gz | |
| PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000438/ScoringFiles/PGS000438.txt.gz | |
| PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 2,111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000440/ScoringFiles/PGS000440.txt.gz | |
| PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,267 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000479/ScoringFiles/PGS000479.txt.gz | |
| PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 177 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000443/ScoringFiles/PGS000443.txt.gz | |
| PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000446/ScoringFiles/PGS000446.txt.gz | |
| PGS000460 (PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 4,279,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000460/ScoringFiles/PGS000460.txt.gz | |
| PGS000461 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 13 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000461/ScoringFiles/PGS000461.txt.gz | |
| PGS000463 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000463/ScoringFiles/PGS000463.txt.gz | |
| PGS000466 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Squamous cell carcinoma | squamous cell carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000466/ScoringFiles/PGS000466.txt.gz | |
| PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000487/ScoringFiles/PGS000487.txt.gz | |
| PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/PGS000492.txt.gz | |
| PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/PGS000494.txt.gz | |
| PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000505/ScoringFiles/PGS000505.txt.gz | |
| PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/PGS000508.txt.gz | |
| PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 118,388 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000511/ScoringFiles/PGS000511.txt.gz | |
| PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000521/ScoringFiles/PGS000521.txt.gz | |
| PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000527/ScoringFiles/PGS000527.txt.gz | |
| PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 174 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/PGS000530.txt.gz | |
| PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000533/ScoringFiles/PGS000533.txt.gz | |
| PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,484 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000535/ScoringFiles/PGS000535.txt.gz | |
| PGS000554 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 1,115,189 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000554/ScoringFiles/PGS000554.txt.gz | |
| PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz | |
| PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,236 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz | |
| PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz | |
| PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz | |
| PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000598/ScoringFiles/PGS000598.txt.gz | |
| PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 250 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000600/ScoringFiles/PGS000600.txt.gz | |
| PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 44 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000604/ScoringFiles/PGS000604.txt.gz | |
| PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,095,241 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000607/ScoringFiles/PGS000607.txt.gz | |
| PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 24,359 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000616/ScoringFiles/PGS000616.txt.gz | |
| PGS000619 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain and nervous system cancer | central nervous system cancer | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000619/ScoringFiles/PGS000619.txt.gz | |
| PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Thyroid cancer | thyroid carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000635/ScoringFiles/PGS000635.txt.gz | |
| PGS000639 (PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Hodgkin's disease | Hodgkins lymphoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000639/ScoringFiles/PGS000639.txt.gz | |
| PGS000645 (PRSWEB_PHECODE204.1_C-LYMPHOID-LEUKAEMIA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lymphoid leukemia | lymphoid leukemia | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000645/ScoringFiles/PGS000645.txt.gz | |
| PGS000646 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000646/ScoringFiles/PGS000646.txt.gz | |
| PGS000353 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000353/ScoringFiles/PGS000353.txt.gz | |
| PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 179 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000356/ScoringFiles/PGS000356.txt.gz | |
| PGS000358 (PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Oral cavity cancer | oral cavity cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000358/ScoringFiles/PGS000358.txt.gz | |
| PGS000365 (PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,070,434 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000365/ScoringFiles/PGS000365.txt.gz | |
| PGS000366 (PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Esophageal cancer | esophageal cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000366/ScoringFiles/PGS000366.txt.gz | |
| PGS000369 (PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 81 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000369/ScoringFiles/PGS000369.txt.gz | |
| PGS000373 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colorectal cancer | colorectal cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000373/ScoringFiles/PGS000373.txt.gz | |
| PGS000378 (PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Colon cancer | colon carcinoma | 1,111,399 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000378/ScoringFiles/PGS000378.txt.gz | |
| PGS000383 (PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of rectum, rectosigmoid junction, and anus | rectum cancer, rectosigmoid junction neoplasm |
1,078,799 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000383/ScoringFiles/PGS000383.txt.gz | |
| PGS000387 (PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Respiratory system cancer | respiratory system cancer | 879,334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000387/ScoringFiles/PGS000387.txt.gz | |
| PGS000390 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Lung and bronchus cancer | tracheal cancer, bronchus cancer, lung cancer |
21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000390/ScoringFiles/PGS000390.txt.gz | |
| PGS000413 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000413/ScoringFiles/PGS000413.txt.gz | |
| PGS000416 (PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000416/ScoringFiles/PGS000416.txt.gz | |
| PGS000430 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000430/ScoringFiles/PGS000430.txt.gz | |
| PGS000431 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Melanomas of skin (diagnosis or history) | melanoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000431/ScoringFiles/PGS000431.txt.gz | |
| PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000434/ScoringFiles/PGS000434.txt.gz | |
| PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000442/ScoringFiles/PGS000442.txt.gz | |
| PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 7,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000444/ScoringFiles/PGS000444.txt.gz | |
| PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000445/ScoringFiles/PGS000445.txt.gz | |
| PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 183 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000448/ScoringFiles/PGS000448.txt.gz | |
| PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000453/ScoringFiles/PGS000453.txt.gz | |
| PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000456/ScoringFiles/PGS000456.txt.gz | |
| PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000472/ScoringFiles/PGS000472.txt.gz | |
| PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000485/ScoringFiles/PGS000485.txt.gz | |
| PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 79 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/PGS000488.txt.gz | |
| PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,142 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000501/ScoringFiles/PGS000501.txt.gz | |
| PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 61,635 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000503/ScoringFiles/PGS000503.txt.gz | |
| PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,682 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/PGS000510.txt.gz | |
| PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000513/ScoringFiles/PGS000513.txt.gz | |
| PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 6,977 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000516/ScoringFiles/PGS000516.txt.gz | |
| PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/PGS000518.txt.gz | |
| PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,376 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000519/ScoringFiles/PGS000519.txt.gz | |
| PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 270 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000523/ScoringFiles/PGS000523.txt.gz | |
| PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/PGS000524.txt.gz | |
| PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/PGS000528.txt.gz | |
| PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 363 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000537/ScoringFiles/PGS000537.txt.gz | |
| PGS000543 (PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other female genital organs | female reproductive system neoplasm | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000543/ScoringFiles/PGS000543.txt.gz | |
| PGS000544 (PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000544/ScoringFiles/PGS000544.txt.gz | |
| PGS000545 (PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000545/ScoringFiles/PGS000545.txt.gz | |
| PGS000547 (PRSWEB_PHECODE184.11_Phelan-EPOC_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000547/ScoringFiles/PGS000547.txt.gz | |
| PGS000553 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000553/ScoringFiles/PGS000553.txt.gz | |
| PGS000560 (PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000560/ScoringFiles/PGS000560.txt.gz | |
| PGS000563 (PRSWEB_PHECODE184.11_Phelan-SIOC_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of ovary | ovarian neoplasm | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000563/ScoringFiles/PGS000563.txt.gz | |
| PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz | |
| PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 100 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz | |
| PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz | |
| PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 97 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000594/ScoringFiles/PGS000594.txt.gz | |
| PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000601/ScoringFiles/PGS000601.txt.gz | |
| PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,097,063 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000608/ScoringFiles/PGS000608.txt.gz | |
| PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Bladder cancer | urinary bladder carcinoma | 1,130 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000609/ScoringFiles/PGS000609.txt.gz | |
| PGS000618 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Brain and nervous system cancer | central nervous system cancer | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000618/ScoringFiles/PGS000618.txt.gz | |
| PGS000640 (PRSWEB_PHECODE201_UKBB-SAIGE-HRC-X201_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Hodgkin's disease | Hodgkins lymphoma | 1,119,335 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000640/ScoringFiles/PGS000640.txt.gz | |
| PGS000641 (PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Non-Hodgkin's lymphoma | non-Hodgkins lymphoma | 12 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000641/ScoringFiles/PGS000641.txt.gz | |
| PGS000643 (PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Nodular lymphoma | follicular lymphoma | 1,048,780 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000643/ScoringFiles/PGS000643.txt.gz | |
| PGS000647 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000647/ScoringFiles/PGS000647.txt.gz | |
| PGS000651 (PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Chronic lymphocytic leukemia | chronic lymphocytic leukemia | 76 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000651/ScoringFiles/PGS000651.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM001257 | PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.649] β: 0.43 (0.0358) |
AUROC: 0.616 [0.597, 0.636] | Nagelkerke's Pseudo-R²: 0.0418 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 |
| PPM001205 | PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.188 [1.158, 1.22] β: 0.172 (0.0133) |
AUROC: 0.549 [0.542, 0.556] | Nagelkerke's Pseudo-R²: 0.00537 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.82 [1.48, 2.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001206 | PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.22 [1.149, 1.295] β: 0.199 (0.0304) |
AUROC: 0.548 [0.53, 0.564] | Nagelkerke's Pseudo-R²: 0.00934 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.18, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001208 | PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.225 [1.155, 1.299] β: 0.203 (0.0301) |
AUROC: 0.546 [0.529, 0.562] | Nagelkerke's Pseudo-R²: 0.00979 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 2.11 [1.34, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001209 | PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.2 [1.169, 1.231] β: 0.182 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.4, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001211 | PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.424 [1.387, 1.461] β: 0.353 (0.0132) |
AUROC: 0.597 [0.59, 0.604] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.19] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001212 | PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.509 [1.418, 1.605] β: 0.411 (0.0314) |
AUROC: 0.613 [0.595, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.55, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001214 | PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.43 [1.346, 1.52] β: 0.358 (0.0311) |
AUROC: 0.597 [0.58, 0.612] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.98 [1.98, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001042 | PGS000357 (PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608) |
PSS000535| European Ancestry| 6,328 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of mouth | OR: 1.111 [1.021, 1.208] β: 0.105 (0.0427) |
AUROC: 0.519 [0.498, 0.542] | Nagelkerke's Pseudo-R²: 0.0021 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.26 [0.585, 2.73] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE145_C3-LIP-ORAL-PHARYNX_PT_MGI_20200608 |
| PPM001045 | PGS000360 (PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.282 [1.09, 1.508] β: 0.249 (0.0827) |
AUROC: 0.57 [0.522, 0.618] | Nagelkerke's Pseudo-R²: 0.0112 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.14 [0.649, 7.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_C32_LASSOSUM_MGI_20200608 |
| PPM001048 | PGS000363 (PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.249 [1.075, 1.45] β: 0.222 (0.0762) |
AUROC: 0.564 [0.525, 0.604] | Nagelkerke's Pseudo-R²: 0.0089 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.07, 7.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C15_PRS-CS_MGI_20200608 |
| PPM001054 | PGS000369 (PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.214 [1.117, 1.32] β: 0.194 (0.0426) |
AUROC: 0.553 [0.525, 0.577] | Nagelkerke's Pseudo-R²: 0.00671 Brier score: 0.0828 Odds Ratio (OR, top 1% vs. Rest): 3.04 [1.79, 5.17] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_PT_MGI_20200608 |
| PPM001057 | PGS000372 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.279 [1.225, 1.335] β: 0.246 (0.0218) |
AUROC: 0.565 [0.551, 0.577] | Nagelkerke's Pseudo-R²: 0.0111 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.1 [1.53, 2.89] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_PT_UKB_20200608 |
| PPM001061 | PGS000376 (PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.177 [1.069, 1.297] β: 0.163 (0.0491) |
AUROC: 0.547 [0.518, 0.576] | Nagelkerke's Pseudo-R²: 0.0046 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 1.65 [0.753, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C18_PRS-CS_MGI_20200608 |
| PPM001063 | PGS000378 (PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.141 [1.038, 1.254] β: 0.132 (0.0484) |
AUROC: 0.536 [0.509, 0.565] | Nagelkerke's Pseudo-R²: 0.00301 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 1.82 [0.867, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C3-COLON_PRS-CS_MGI_20200608 |
| PPM001067 | PGS000382 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.247 [1.134, 1.371] β: 0.221 (0.0483) |
AUROC: 0.567 [0.54, 0.594] | Nagelkerke's Pseudo-R²: 0.00899 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.17 [0.477, 2.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_LASSOSUM_MGI_20200608 |
| PPM001070 | PGS000385 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608) |
PSS000565| European Ancestry| 3,591 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Pancreatic cancer | OR: 1.384 [1.235, 1.552] β: 0.325 (0.0583) |
AUROC: 0.589 [0.559, 0.622] | Nagelkerke's Pseudo-R²: 0.019 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [1.19, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_P_5e-08_UKB_20200608 |
| PPM001073 | PGS000388 (PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.132 [1.024, 1.25] β: 0.124 (0.0508) |
AUROC: 0.533 [0.505, 0.562] | Nagelkerke's Pseudo-R²: 0.00265 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.96 [0.926, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_C3-BRONCHUS-LUNG_PRS-CS_MGI_20200608 |
| PPM001076 | PGS000391 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.12 [1.015, 1.237] β: 0.114 (0.0507) |
AUROC: 0.529 [0.503, 0.558] | Nagelkerke's Pseudo-R²: 0.00234 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.75 [0.796, 3.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_MGI_20200608 |
| PPM001157 | PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.343 [1.266, 1.426] β: 0.295 (0.0303) |
AUROC: 0.579 [0.561, 0.597] | Nagelkerke's Pseudo-R²: 0.0204 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.49, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608 |
| PPM001079 | PGS000394 (PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.149 [1.04, 1.269] β: 0.139 (0.0509) |
AUROC: 0.539 [0.508, 0.568] | Nagelkerke's Pseudo-R²: 0.00329 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.18 [1.06, 4.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_LUNG-CANCER-MESOT_PRS-CS_MGI_20200608 |
| PPM001082 | PGS000397 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.114 [1.009, 1.23] β: 0.108 (0.0507) |
AUROC: 0.528 [0.503, 0.556] | Nagelkerke's Pseudo-R²: 0.00202 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.03 [0.387, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_LASSOSUM_MGI_20200608 |
| PPM001085 | PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.395] β: 0.294 (0.0197) |
AUROC: 0.581 [0.57, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.63, 2.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 |
| PPM001088 | PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.359 [1.307, 1.413] β: 0.307 (0.0199) |
AUROC: 0.584 [0.573, 0.594] | Nagelkerke's Pseudo-R²: 0.0219 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.2, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 |
| PPM001091 | PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.392 [1.339, 1.447] β: 0.331 (0.0199) |
AUROC: 0.591 [0.581, 0.602] | Nagelkerke's Pseudo-R²: 0.0249 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.89, 3.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 |
| PPM001095 | PGS000410 (PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.399 [1.327, 1.476] β: 0.336 (0.0272) |
AUROC: 0.578 [0.562, 0.594] | Nagelkerke's Pseudo-R²: 0.0239 Brier score: 0.0956 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.79, 3.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608 |
| PPM001098 | PGS000413 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.27 [1.199, 1.346] β: 0.239 (0.0294) |
AUROC: 0.568 [0.552, 0.584] | Nagelkerke's Pseudo-R²: 0.0109 Brier score: 0.0964 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.35, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608 |
| PPM001101 | PGS000416 (PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.473 [1.394, 1.557] β: 0.388 (0.0282) |
AUROC: 0.598 [0.582, 0.613] | Nagelkerke's Pseudo-R²: 0.0297 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.88 [1.96, 4.21] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608 |
| PPM001103 | PGS000418 (PRSWEB_PHECODE172.1_C43_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.473 [1.394, 1.557] β: 0.388 (0.0282) |
AUROC: 0.598 [0.582, 0.613] | Nagelkerke's Pseudo-R²: 0.0297 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.88 [1.96, 4.21] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_PT_MGI_20200608 |
| PPM001106 | PGS000421 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.37, 1.541] β: 0.374 (0.03) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.58, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608 |
| PPM001110 | PGS000425 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.369, 1.542] β: 0.374 (0.0304) |
AUROC: 0.601 [0.585, 0.617] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.7, 3.8] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608 |
| PPM001118 | PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.367 [1.31, 1.426] β: 0.312 (0.0215) |
AUROC: 0.584 [0.572, 0.598] | Nagelkerke's Pseudo-R²: 0.0215 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.73 [2.01, 3.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 |
| PPM001121 | PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.305, 1.42] β: 0.308 (0.0216) |
AUROC: 0.584 [0.571, 0.596] | Nagelkerke's Pseudo-R²: 0.021 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.61, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 |
| PPM001124 | PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.348 [1.293, 1.407] β: 0.299 (0.0216) |
AUROC: 0.583 [0.57, 0.595] | Nagelkerke's Pseudo-R²: 0.0197 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.57, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 |
| PPM001127 | PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.417] β: 0.306 (0.0217) |
AUROC: 0.584 [0.572, 0.595] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.71, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 |
| PPM001130 | PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.334 [1.264, 1.409] β: 0.289 (0.0278) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0184 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.72, 3.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 |
| PPM001132 | PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.398 [1.322, 1.477] β: 0.335 (0.0282) |
AUROC: 0.591 [0.575, 0.607] | Nagelkerke's Pseudo-R²: 0.0237 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.5 [1.68, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 |
| PPM001135 | PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.079 [1.022, 1.139] β: 0.0759 (0.0278) |
AUROC: 0.504 [0.489, 0.52] | Nagelkerke's Pseudo-R²: 0.00145 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.882, 2.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 |
| PPM001138 | PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 |
| PPM001142 | PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.535 [1.493, 1.579] β: 0.429 (0.0144) |
AUROC: 0.617 [0.609, 0.625] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.11 [2.6, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 |
| PPM001145 | PGS000460 (PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.096 [1.025, 1.172] β: 0.0917 (0.0344) |
AUROC: 0.523 [0.503, 0.543] | Nagelkerke's Pseudo-R²: 0.00155 Brier score: 0.0996 Odds Ratio (OR, top 1% vs. Rest): 1.56 [0.892, 2.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608 |
| PPM001148 | PGS000463 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.448 [1.356, 1.546] β: 0.37 (0.0335) |
AUROC: 0.593 [0.573, 0.613] | Nagelkerke's Pseudo-R²: 0.0268 Brier score: 0.0977 Odds Ratio (OR, top 1% vs. Rest): 3.74 [2.46, 5.68] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608 |
| PPM001151 | PGS000466 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | β: 0.283 (0.0138) OR: 1.327 [1.292, 1.364] |
AUROC: 0.57 [0.562, 0.578] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 1.75 [1.4, 2.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608 |
| PPM001154 | PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.09 [1.001, 1.188] β: 0.0865 (0.0437) |
AUROC: 0.524 [0.499, 0.549] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.0939 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.703, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 |
| PPM001160 | PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.349 [1.269, 1.434] β: 0.299 (0.0312) |
AUROC: 0.586 [0.57, 0.603] | Nagelkerke's Pseudo-R²: 0.0196 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.59 [0.962, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608 |
| PPM001163 | PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.411 [1.328, 1.5] β: 0.344 (0.031) |
AUROC: 0.595 [0.578, 0.611] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.31 [1.47, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608 |
| PPM001166 | PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.246, 1.406] β: 0.28 (0.0307) |
AUROC: 0.578 [0.56, 0.596] | Nagelkerke's Pseudo-R²: 0.0183 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.29, 3.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608 |
| PPM001169 | PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.12 [1.056, 1.187] β: 0.113 (0.0297) |
AUROC: 0.52 [0.504, 0.538] | Nagelkerke's Pseudo-R²: 0.00286 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.817, 2.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_D05_PT_MGI_20200608 |
| PPM001172 | PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608 |
| PPM001175 | PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | β: 0.221 (0.0132) OR: 1.248 [1.216, 1.28] |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001178 | PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.31 [1.234, 1.391] β: 0.27 (0.0306) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0173 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.84 [1.14, 2.97] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
| PPM001181 | PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.289, 1.358] β: 0.28 (0.0133) |
AUROC: 0.576 [0.568, 0.583] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.86, 2.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
| PPM001195 | PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.612 [1.57, 1.656] β: 0.478 (0.0136) |
AUROC: 0.63 [0.623, 0.637] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.83, 3.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001198 | PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.402 [1.32, 1.489] β: 0.338 (0.0307) |
AUROC: 0.595 [0.577, 0.612] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.12, 2.91] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608 |
| PPM001201 | PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.477 [1.39, 1.57] β: 0.39 (0.031) |
AUROC: 0.609 [0.592, 0.624] | Nagelkerke's Pseudo-R²: 0.034 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.21, 3.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608 |
| PPM001273 | PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.127 [2.043, 2.215] β: 0.755 (0.0206) |
AUROC: 0.699 [0.69, 0.71] | Nagelkerke's Pseudo-R²: 0.0943 Brier score: 0.0794 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 |
| PPM001204 | PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.151 [1.084, 1.221] β: 0.14 (0.0305) |
AUROC: 0.539 [0.52, 0.556] | Nagelkerke's Pseudo-R²: 0.00453 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.907, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001207 | PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.201 [1.171, 1.233] β: 0.183 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.00619 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.73 [1.41, 2.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001210 | PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.427 [1.343, 1.516] β: 0.356 (0.0309) |
AUROC: 0.597 [0.58, 0.614] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.28 [1.46, 3.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001188 | PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.656 [1.554, 1.766] β: 0.505 (0.0326) |
AUROC: 0.634 [0.618, 0.65] | Nagelkerke's Pseudo-R²: 0.0546 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.78, 5.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001192 | PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.772 [1.659, 1.891] β: 0.572 (0.0334) |
AUROC: 0.651 [0.635, 0.666] | Nagelkerke's Pseudo-R²: 0.0661 Brier score: 0.133 Odds Ratio (OR, top 1% vs. Rest): 3.22 [2.15, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001213 | PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.554] β: 0.414 (0.0136) |
AUROC: 0.614 [0.607, 0.62] | Nagelkerke's Pseudo-R²: 0.0303 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 2.98 [2.52, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001216 | PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.501 [1.411, 1.596] β: 0.406 (0.0314) |
AUROC: 0.61 [0.594, 0.626] | Nagelkerke's Pseudo-R²: 0.037 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.29 [1.47, 3.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
| PPM001219 | PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.443 [1.406, 1.481] β: 0.367 (0.0132) |
AUROC: 0.601 [0.594, 0.608] | Nagelkerke's Pseudo-R²: 0.0246 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.5 [2.09, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001222 | PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.498 [1.408, 1.593] β: 0.404 (0.0314) |
AUROC: 0.609 [0.592, 0.626] | Nagelkerke's Pseudo-R²: 0.0353 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.44 [2.31, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001225 | PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.528 [1.489, 1.569] β: 0.424 (0.0134) |
AUROC: 0.615 [0.607, 0.622] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.55 [3.04, 4.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001228 | PGS000543 (PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608) |
PSS000551| European Ancestry| 4,905 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other female genital organs | OR: 1.144 [1.043, 1.255] β: 0.135 (0.0472) |
AUROC: 0.51 [0.483, 0.537] | Nagelkerke's Pseudo-R²: 0.00332 Brier score: 0.0836 Odds Ratio (OR, top 1% vs. Rest): 1.63 [0.743, 3.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608 |
| PPM001231 | PGS000546 (PRSWEB_PHECODE184.11_Phelan-ENOC_PRS-CS_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.119 [1.017, 1.231] β: 0.112 (0.0488) |
AUROC: 0.526 [0.498, 0.554] | Nagelkerke's Pseudo-R²: 0.00221 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.97 [0.973, 4.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-ENOC_PRS-CS_UKB_20200608 |
| PPM001234 | PGS000549 (PRSWEB_PHECODE184.11_Phelan-IEOC_P_5e-08_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.263 [1.15, 1.387] β: 0.234 (0.0479) |
AUROC: 0.567 [0.539, 0.595] | Nagelkerke's Pseudo-R²: 0.00996 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.839, 3.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-IEOC_P_5e-08_UKB_20200608 |
| PPM001237 | PGS000552 (PRSWEB_PHECODE184.11_Phelan-IEOC_LASSOSUM_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.19 [1.084, 1.308] β: 0.174 (0.048) |
AUROC: 0.552 [0.523, 0.58] | Nagelkerke's Pseudo-R²: 0.00552 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.97 [0.97, 3.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-IEOC_LASSOSUM_UKB_20200608 |
| PPM001240 | PGS000555 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_PT_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.133 [1.03, 1.245] β: 0.125 (0.0483) |
AUROC: 0.539 [0.513, 0.568] | Nagelkerke's Pseudo-R²: 0.00282 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.18 [1.11, 4.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-LSASBOC_PT_UKB_20200608 |
| PPM001243 | PGS000558 (PRSWEB_PHECODE184.11_Phelan-OCCC_LASSOSUM_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.207 [1.102, 1.321] β: 0.188 (0.0463) |
AUROC: 0.546 [0.52, 0.574] | Nagelkerke's Pseudo-R²: 0.00676 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.839, 3.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-OCCC_LASSOSUM_UKB_20200608 |
| PPM001246 | PGS000561 (PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_MGI_20200608) |
PSS000550| European Ancestry| 1,904 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.185 [1.011, 1.39] β: 0.17 (0.0812) |
AUROC: 0.552 [0.513, 0.598] | Nagelkerke's Pseudo-R²: 0.00517 Brier score: 0.0827 |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_MGI_20200608 |
| PPM001249 | PGS000564 (PRSWEB_PHECODE184.11_Phelan-SIOC_LASSOSUM_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.215 [1.106, 1.336] β: 0.195 (0.0481) |
AUROC: 0.556 [0.529, 0.583] | Nagelkerke's Pseudo-R²: 0.00692 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.839, 3.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_LASSOSUM_UKB_20200608 |
| PPM001258 | PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.603 [1.495, 1.718] β: 0.472 (0.0355) |
AUROC: 0.622 [0.603, 0.641] | Nagelkerke's Pseudo-R²: 0.0497 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 |
| PPM001260 | PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.577 [1.47, 1.692] β: 0.456 (0.0359) |
AUROC: 0.619 [0.601, 0.637] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608 |
| PPM001264 | PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.747 [1.626, 1.876] β: 0.558 (0.0364) |
AUROC: 0.646 [0.627, 0.664] | Nagelkerke's Pseudo-R²: 0.0675 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 |
| PPM001267 | PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.957 [1.882, 2.035] β: 0.671 (0.0201) |
AUROC: 0.681 [0.671, 0.692] | Nagelkerke's Pseudo-R²: 0.0776 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 |
| PPM001270 | PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.907 [1.771, 2.053] β: 0.645 (0.0378) |
AUROC: 0.67 [0.652, 0.688] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 |
| PPM001276 | PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.608 [1.498, 1.725] β: 0.475 (0.0359) |
AUROC: 0.627 [0.608, 0.645] | Nagelkerke's Pseudo-R²: 0.051 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 |
| PPM001279 | PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.227 [1.029, 1.464] β: 0.205 (0.0899) |
AUROC: 0.558 [0.506, 0.606] | Nagelkerke's Pseudo-R²: 0.00729 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.04 [0.183, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 |
| PPM001282 | PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.667 [1.296, 2.143] β: 0.511 (0.128) |
AUROC: 0.656 [0.593, 0.717] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 2.72 [0.568, 13.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 |
| PPM001285 | PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.619 [1.267, 2.067] β: 0.482 (0.125) |
AUROC: 0.636 [0.565, 0.698] | Nagelkerke's Pseudo-R²: 0.046 Brier score: 0.0839 Odds Ratio (OR, top 1% vs. Rest): 6.35 [1.81, 22.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 |
| PPM001288 | PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.625 [1.27, 2.079] β: 0.485 (0.126) |
AUROC: 0.625 [0.557, 0.693] | Nagelkerke's Pseudo-R²: 0.044 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 6.05 [1.73, 21.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 |
| PPM001292 | PGS000607 (PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.096 [1.018, 1.18] β: 0.0918 (0.0377) |
AUROC: 0.531 [0.509, 0.551] | Nagelkerke's Pseudo-R²: 0.00156 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.671 [0.279, 1.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_20001-1035_PRS-CS_MGI_20200608 |
| PPM001294 | PGS000609 (PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.106 [1.027, 1.191] β: 0.101 (0.0376) |
AUROC: 0.528 [0.508, 0.549] | Nagelkerke's Pseudo-R²: 0.00205 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.69 [0.934, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C67_LASSOSUM_MGI_20200608 |
| PPM001297 | PGS000612 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_MGI_20200608 |
| PPM001300 | PGS000615 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.007, 1.167] β: 0.0809 (0.0376) |
AUROC: 0.519 [0.498, 0.541] | Nagelkerke's Pseudo-R²: 0.00137 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.788 [0.35, 1.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PT_MGI_20200608 |
| PPM001304 | PGS000619 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608) |
PSS000578| European Ancestry| 3,110 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain and nervous system | OR: 1.564 [1.396, 1.753] β: 0.448 (0.0581) |
AUROC: 0.622 [0.59, 0.653] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.34, 6.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_PT_UKB_20200608 |
| PPM001307 | PGS000622 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608) |
PSS000577| European Ancestry| 3,020 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.486 [1.315, 1.679] β: 0.396 (0.0624) |
AUROC: 0.605 [0.569, 0.639] | Nagelkerke's Pseudo-R²: 0.0289 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 3.38 [1.59, 7.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_UKB_20200608 |
| PPM001310 | PGS000625 (PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.142 [1.004, 1.299] β: 0.133 (0.0657) |
AUROC: 0.53 [0.492, 0.57] | Nagelkerke's Pseudo-R²: 0.00328 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.28 [0.88, 5.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_UKBB-SAIGE-HRC-X191.11_PT_MGI_20200608 |
| PPM001314 | PGS000629 (PRSWEB_PHECODE193_C73_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | β: 0.114 (0.0517) OR: 1.121 [1.013, 1.24] |
AUROC: 0.52 [0.488, 0.55] | Nagelkerke's Pseudo-R²: 0.00247 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.15 [1.01, 4.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C73_PT_MGI_20200608 |
| PPM001317 | PGS000632 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.568 [1.412, 1.74] β: 0.45 (0.0532) |
AUROC: 0.618 [0.587, 0.647] | Nagelkerke's Pseudo-R²: 0.0365 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 5.14 [2.94, 8.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_MGI_20200608 |
| PPM001320 | PGS000635 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.315 [1.194, 1.448] β: 0.274 (0.0492) |
AUROC: 0.569 [0.538, 0.598] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.65 [0.708, 3.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PT_MGI_20200608 |
| PPM001323 | PGS000638 (PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_P_5e-08_MGI_20200608) |
PSS000559| European Ancestry| 775 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Hodgkin's disease | OR: 1.377 [1.08, 1.755] β: 0.32 (0.124) |
AUROC: 0.601 [0.535, 0.671] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.62 [0.258, 10.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_P_5e-08_MGI_20200608 |
| PPM001039 | PGS000354 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.079 [1.039, 1.119] β: 0.0758 (0.0189) |
AUROC: 0.521 [0.51, 0.532] | Nagelkerke's Pseudo-R²: 0.00112 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.887, 1.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PRS-CS_MGI_20200608 |
| PPM001330 | PGS000645 (PRSWEB_PHECODE204.1_C-LYMPHOID-LEUKAEMIA_PT_MGI_20200608) |
PSS000562| European Ancestry| 957 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia | OR: 1.358 [1.113, 1.657] β: 0.306 (0.102) |
AUROC: 0.578 [0.517, 0.642] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 3.69 [1.01, 13.4] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.1_C-LYMPHOID-LEUKAEMIA_PT_MGI_20200608 |
| PPM001333 | PGS000648 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_MGI_20200608) |
PSS000561| European Ancestry| 756 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 2.124 [1.648, 2.738] β: 0.753 (0.13) |
AUROC: 0.696 [0.621, 0.764] | Nagelkerke's Pseudo-R²: 0.102 Brier score: 0.0776 Odds Ratio (OR, top 1% vs. Rest): 12.9 [4.45, 37.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_MGI_20200608 |
| PPM001336 | PGS000651 (PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_LASSOSUM_MGI_20200608) |
PSS000561| European Ancestry| 756 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 1.32 [1.041, 1.675] β: 0.278 (0.121) |
AUROC: 0.573 [0.503, 0.644] | Nagelkerke's Pseudo-R²: 0.0145 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 4.84 [1.23, 19.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_LASSOSUM_MGI_20200608 |
| PPM001339 | PGS000654 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608) |
PSS000582| European Ancestry| 2,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.316 [1.156, 1.499] β: 0.275 (0.0662) |
AUROC: 0.576 [0.536, 0.616] | Nagelkerke's Pseudo-R²: 0.0137 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.2 [0.854, 5.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_PT_UKB_20200608 |
| PPM001038 | PGS000353 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.08 [1.041, 1.122] β: 0.0774 (0.0191) |
AUROC: 0.515 [0.503, 0.526] | Nagelkerke's Pseudo-R²: 0.00151 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.48 [1.04, 2.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_P_5e-08_MGI_20200608 |
| PPM001040 | PGS000355 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.084 [1.044, 1.125] β: 0.0803 (0.0191) |
AUROC: 0.517 [0.506, 0.527] | Nagelkerke's Pseudo-R²: 0.00167 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.42 [1.0, 2.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_PT_MGI_20200608 |
| PPM001041 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS000533| European Ancestry| 15,286 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Any Cancer | OR: 1.106 [1.065, 1.148] β: 0.101 (0.0192) |
AUROC: 0.523 [0.512, 0.535] | Nagelkerke's Pseudo-R²: 0.00294 Brier score: 0.182 Odds Ratio (OR, top 1% vs. Rest): 1.61 [1.14, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608 |
| PPM001043 | PGS000358 (PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608) |
PSS000535| European Ancestry| 6,328 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of mouth | OR: 1.116 [1.024, 1.216] β: 0.11 (0.0438) |
AUROC: 0.528 [0.502, 0.552] | Nagelkerke's Pseudo-R²: 0.00207 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.63 [0.812, 3.26] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE145_UKBB-SAIGE-HRC-X145_PRS-CS_MGI_20200608 |
| PPM001044 | PGS000359 (PRSWEB_PHECODE145.2_C3-TONGUENAS_PRS-CS_MGI_20200608) |
PSS000534| European Ancestry| 2,841 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of tongue | OR: 1.142 [1.006, 1.297] β: 0.133 (0.0647) |
AUROC: 0.538 [0.501, 0.575] | Nagelkerke's Pseudo-R²: 0.00325 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.69 [0.61, 4.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE145.2_C3-TONGUENAS_PRS-CS_MGI_20200608 |
| PPM001046 | PGS000361 (PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.195 [1.014, 1.408] β: 0.178 (0.0836) |
AUROC: 0.55 [0.504, 0.593] | Nagelkerke's Pseudo-R²: 0.00551 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.382, 5.94] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_C3-LARYNX_LASSOSUM_MGI_20200608 |
| PPM001047 | PGS000362 (PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608) |
PSS000536| European Ancestry| 1,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of larynx | OR: 1.195 [1.023, 1.396] β: 0.178 (0.0793) |
AUROC: 0.543 [0.494, 0.59] | Nagelkerke's Pseudo-R²: 0.00609 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.52 [0.384, 5.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE149.4_UKBB-SAIGE-HRC-X149.4_PT_MGI_20200608 |
| PPM001049 | PGS000364 (PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.203 [1.041, 1.391] β: 0.185 (0.074) |
AUROC: 0.551 [0.51, 0.588] | Nagelkerke's Pseudo-R²: 0.00648 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.81 [0.56, 5.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C15_LASSOSUM_MGI_20200608 |
| PPM001050 | PGS000365 (PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.187 [1.021, 1.38] β: 0.171 (0.0769) |
AUROC: 0.553 [0.514, 0.596] | Nagelkerke's Pseudo-R²: 0.00521 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.329, 4.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_C3-OESOPHAGUS_PRS-CS_MGI_20200608 |
| PPM001052 | PGS000367 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.198 [1.102, 1.302] β: 0.181 (0.0425) |
AUROC: 0.55 [0.522, 0.574] | Nagelkerke's Pseudo-R²: 0.00586 Brier score: 0.0828 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.21, 4.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_MGI_20200608 |
| PPM001053 | PGS000368 (PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.516 [1.451, 1.585] β: 0.416 (0.0225) |
AUROC: 0.612 [0.6, 0.625] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.85 [2.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_P_5e-08_UKB_20200608 |
| PPM001055 | PGS000370 (PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.547 [1.48, 1.617] β: 0.436 (0.0226) |
AUROC: 0.617 [0.605, 0.63] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 4.0 [3.11, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_CRC-Huyghe_PT_UKB_20200608 |
| PPM001133 | PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.411 [1.335, 1.491] β: 0.344 (0.0282) |
AUROC: 0.587 [0.57, 0.604] | Nagelkerke's Pseudo-R²: 0.0254 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.03, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 |
| PPM001056 | PGS000371 (PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608) |
PSS000564| European Ancestry| 24,996 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.254 [1.202, 1.309] β: 0.226 (0.0217) |
AUROC: 0.561 [0.548, 0.573] | Nagelkerke's Pseudo-R²: 0.00946 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_GWAS-Catalog-r2019-05-03-X153_P_5e-08_UKB_20200608 |
| PPM001058 | PGS000373 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.189 [1.093, 1.293] β: 0.173 (0.0428) |
AUROC: 0.548 [0.523, 0.572] | Nagelkerke's Pseudo-R²: 0.00529 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.71 [0.882, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PRS-CS_MGI_20200608 |
| PPM001060 | PGS000375 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.113 [1.024, 1.21] β: 0.107 (0.0425) |
AUROC: 0.53 [0.503, 0.555] | Nagelkerke's Pseudo-R²: 0.00205 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 2.76 [1.59, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_LASSOSUM_MGI_20200608 |
| PPM001062 | PGS000377 (PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.174 [1.066, 1.292] β: 0.16 (0.049) |
AUROC: 0.545 [0.518, 0.574] | Nagelkerke's Pseudo-R²: 0.00441 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.4 [0.607, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C18_LASSOSUM_MGI_20200608 |
| PPM001064 | PGS000379 (PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.143 [1.038, 1.258] β: 0.134 (0.049) |
AUROC: 0.536 [0.51, 0.567] | Nagelkerke's Pseudo-R²: 0.00302 Brier score: 0.0832 Odds Ratio (OR, top 1% vs. Rest): 0.757 [0.252, 2.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_C3-COLON_LASSOSUM_MGI_20200608 |
| PPM001065 | PGS000380 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.324 [1.203, 1.457] β: 0.281 (0.0489) |
AUROC: 0.569 [0.539, 0.599] | Nagelkerke's Pseudo-R²: 0.0138 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 3.85 [2.19, 6.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PRS-CS_MGI_20200608 |
| PPM001066 | PGS000381 (PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608) |
PSS000538| European Ancestry| 5,031 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colon cancer | OR: 1.212 [1.105, 1.33] β: 0.193 (0.0472) |
AUROC: 0.55 [0.522, 0.577] | Nagelkerke's Pseudo-R²: 0.00703 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.733, 3.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.2_UKBB-SAIGE-HRC-X153.2_PT_MGI_20200608 |
| PPM001068 | PGS000383 (PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608) |
PSS000539| European Ancestry| 3,557 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of rectum, rectosigmoid junction, and anus | OR: 1.126 [1.005, 1.262] β: 0.119 (0.0579) |
AUROC: 0.533 [0.5, 0.567] | Nagelkerke's Pseudo-R²: 0.00257 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.34 [0.491, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.3_C19_PRS-CS_MGI_20200608 |
| PPM001071 | PGS000386 (PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608) |
PSS000565| European Ancestry| 3,591 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Pancreatic cancer | OR: 1.342 [1.199, 1.503] β: 0.294 (0.0577) |
AUROC: 0.579 [0.548, 0.611] | Nagelkerke's Pseudo-R²: 0.0157 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 1.64 [0.655, 4.12] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE157_GWAS-Catalog-r2019-05-03-X157_PT_UKB_20200608 |
| PPM001072 | PGS000387 (PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608) |
PSS000542| European Ancestry| 5,218 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer within the respiratory system | OR: 1.109 [1.008, 1.22] β: 0.103 (0.0486) |
AUROC: 0.53 [0.502, 0.557] | Nagelkerke's Pseudo-R²: 0.0018 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.12, 4.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165_UKBB-SAIGE-HRC-X165_LASSOSUM_MGI_20200608 |
| PPM001074 | PGS000389 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.11 [1.006, 1.225] β: 0.105 (0.0501) |
AUROC: 0.52 [0.492, 0.547] | Nagelkerke's Pseudo-R²: 0.00202 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.19 [1.07, 4.49] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_MGI_20200608 |
| PPM001075 | PGS000390 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608) |
PSS000566| European Ancestry| 12,201 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.194 [1.124, 1.269] β: 0.178 (0.0309) |
AUROC: 0.543 [0.526, 0.562] | Nagelkerke's Pseudo-R²: 0.00583 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 0.852 [0.437, 1.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_P_5e-08_UKB_20200608 |
| PPM001077 | PGS000392 (PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608) |
PSS000566| European Ancestry| 12,201 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.221 [1.149, 1.298] β: 0.2 (0.0313) |
AUROC: 0.552 [0.534, 0.569] | Nagelkerke's Pseudo-R²: 0.00728 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.22, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_GWAS-Catalog-r2019-05-03-X165.1_PT_UKB_20200608 |
| PPM001078 | PGS000393 (PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.149 [1.04, 1.269] β: 0.139 (0.0509) |
AUROC: 0.539 [0.508, 0.568] | Nagelkerke's Pseudo-R²: 0.00329 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.18 [1.06, 4.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_LUNG-CANCER_PRS-CS_MGI_20200608 |
| PPM001080 | PGS000395 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.133 [1.025, 1.252] β: 0.125 (0.051) |
AUROC: 0.533 [0.505, 0.562] | Nagelkerke's Pseudo-R²: 0.00277 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.27 [0.514, 3.12] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PRS-CS_MGI_20200608 |
| PPM001081 | PGS000396 (PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608) |
PSS000541| European Ancestry| 4,698 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bronchus; lung | OR: 1.121 [1.015, 1.238] β: 0.114 (0.0507) |
AUROC: 0.525 [0.496, 0.554] | Nagelkerke's Pseudo-R²: 0.00233 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.08, 4.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE165.1_UKBB-SAIGE-HRC-X165.1_PT_MGI_20200608 |
| PPM001083 | PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.042 [1.003, 1.082] β: 0.0407 (0.0195) |
AUROC: 0.51 [0.499, 0.521] | Nagelkerke's Pseudo-R²: 0.00028 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.7 [1.22, 2.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 |
| PPM001084 | PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.158 [1.116, 1.202] β: 0.147 (0.0189) |
AUROC: 0.513 [0.503, 0.523] | Nagelkerke's Pseudo-R²: 0.00545 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.56 [1.12, 2.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 |
| PPM001086 | PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.396] β: 0.294 (0.0199) |
AUROC: 0.581 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.67, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 |
| PPM001087 | PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.366 [1.314, 1.421] β: 0.312 (0.0198) |
AUROC: 0.586 [0.576, 0.597] | Nagelkerke's Pseudo-R²: 0.0224 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.23 [1.64, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 |
| PPM001089 | PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.369 [1.317, 1.422] β: 0.314 (0.0196) |
AUROC: 0.584 [0.574, 0.594] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.3 [1.72, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 |
| PPM001090 | PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.338 [1.287, 1.391] β: 0.291 (0.0199) |
AUROC: 0.58 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0192 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.81, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 |
| PPM001092 | PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.38 [1.328, 1.434] β: 0.322 (0.0197) |
AUROC: 0.586 [0.575, 0.597] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.26 [1.69, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 |
| PPM001337 | PGS000652 (PRSWEB_PHECODE204.4_C90_PT_MGI_20200608) |
PSS000563| European Ancestry| 908 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.24 [1.005, 1.529] β: 0.215 (0.107) |
AUROC: 0.547 [0.479, 0.613] | Nagelkerke's Pseudo-R²: 0.00945 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 2.6 [0.593, 11.4] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_C90_PT_MGI_20200608 |
| PPM001093 | PGS000408 (PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.384 [1.311, 1.461] β: 0.325 (0.0276) |
AUROC: 0.576 [0.561, 0.593] | Nagelkerke's Pseudo-R²: 0.0217 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.48, 3.42] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608 |
| PPM001096 | PGS000411 (PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.378 [1.308, 1.451] β: 0.32 (0.0265) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0222 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.0 [1.29, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608 |
| PPM001099 | PGS000414 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.44 [1.363, 1.522] β: 0.365 (0.0283) |
AUROC: 0.593 [0.576, 0.609] | Nagelkerke's Pseudo-R²: 0.026 Brier score: 0.0954 Odds Ratio (OR, top 1% vs. Rest): 2.97 [2.02, 4.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608 |
| PPM001100 | PGS000415 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.391 [1.318, 1.467] β: 0.33 (0.0272) |
AUROC: 0.578 [0.562, 0.595] | Nagelkerke's Pseudo-R²: 0.0227 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.55, 3.53] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608 |
| PPM001102 | PGS000417 (PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.228 [1.159, 1.3] β: 0.205 (0.0294) |
AUROC: 0.556 [0.541, 0.571] | Nagelkerke's Pseudo-R²: 0.00812 Brier score: 0.0965 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.2, 2.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608 |
| PPM001104 | PGS000419 (PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.348 [1.279, 1.421] β: 0.299 (0.0268) |
AUROC: 0.565 [0.549, 0.583] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.0959 Odds Ratio (OR, top 1% vs. Rest): 1.93 [1.24, 3.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608 |
| PPM001105 | PGS000420 (PRSWEB_PHECODE172.1_D03_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.066 [1.007, 1.128] β: 0.0639 (0.029) |
AUROC: 0.516 [0.5, 0.533] | Nagelkerke's Pseudo-R²: 0.00074 Brier score: 0.0969 Odds Ratio (OR, top 1% vs. Rest): 1.07 [0.603, 1.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_D03_PT_MGI_20200608 |
| PPM001107 | PGS000422 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608) |
PSS000567| European Ancestry| 14,482 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.539 [1.454, 1.629] β: 0.431 (0.029) |
AUROC: 0.615 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.57 [1.75, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608 |
| PPM001108 | PGS000423 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | β: 0.394 (0.0301) OR: 1.484 [1.399, 1.574] |
AUROC: 0.608 [0.592, 0.623] | Nagelkerke's Pseudo-R²: 0.0289 Brier score: 0.0954 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.0, 4.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608 |
| PPM001109 | PGS000424 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608) |
PSS000567| European Ancestry| 14,482 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.563 [1.475, 1.656] β: 0.447 (0.0294) |
AUROC: 0.619 [0.603, 0.634] | Nagelkerke's Pseudo-R²: 0.035 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 3.12 [2.18, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608 |
| PPM001111 | PGS000426 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608) |
PSS000567| European Ancestry| 14,482 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.551 [1.463, 1.643] β: 0.439 (0.0296) |
AUROC: 0.62 [0.604, 0.635] | Nagelkerke's Pseudo-R²: 0.0335 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.81 [1.93, 4.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608 |
| PPM001112 | PGS000427 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.369, 1.542] β: 0.374 (0.0304) |
AUROC: 0.601 [0.585, 0.617] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.7, 3.8] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608 |
| PPM001113 | PGS000428 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608) |
PSS000567| European Ancestry| 14,482 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.551 [1.463, 1.643] β: 0.439 (0.0296) |
AUROC: 0.62 [0.604, 0.635] | Nagelkerke's Pseudo-R²: 0.0335 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.81 [1.93, 4.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608 |
| PPM001114 | PGS000429 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.503 [1.422, 1.589] β: 0.408 (0.0284) |
AUROC: 0.606 [0.591, 0.622] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0951 Odds Ratio (OR, top 1% vs. Rest): 2.62 [1.77, 3.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608 |
| PPM001116 | PGS000431 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.486 [1.405, 1.571] β: 0.396 (0.0285) |
AUROC: 0.604 [0.587, 0.62] | Nagelkerke's Pseudo-R²: 0.0312 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.97 [2.04, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608 |
| PPM001117 | PGS000432 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.391 [1.318, 1.467] β: 0.33 (0.0273) |
AUROC: 0.582 [0.566, 0.599] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.29, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608 |
| PPM001119 | PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.304, 1.42] β: 0.308 (0.0217) |
AUROC: 0.586 [0.573, 0.598] | Nagelkerke's Pseudo-R²: 0.0208 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.43, 2.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 |
| PPM001120 | PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.415] β: 0.305 (0.0215) |
AUROC: 0.584 [0.572, 0.597] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.99, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 |
| PPM001122 | PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.352 [1.296, 1.409] β: 0.301 (0.0213) |
AUROC: 0.579 [0.566, 0.592] | Nagelkerke's Pseudo-R²: 0.0206 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.6, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 |
| PPM001123 | PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.31 [1.256, 1.367] β: 0.27 (0.0216) |
AUROC: 0.575 [0.562, 0.587] | Nagelkerke's Pseudo-R²: 0.0162 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 |
| PPM001125 | PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.351 [1.296, 1.409] β: 0.301 (0.0215) |
AUROC: 0.581 [0.569, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.87, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 |
| PPM001126 | PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.39 [1.333, 1.449] β: 0.329 (0.0214) |
AUROC: 0.586 [0.574, 0.599] | Nagelkerke's Pseudo-R²: 0.0241 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.94, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 |
| PPM001128 | PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.41 [1.352, 1.471] β: 0.344 (0.0216) |
AUROC: 0.591 [0.579, 0.603] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.89 [2.14, 3.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 |
| PPM001131 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.291 [1.221, 1.366] β: 0.256 (0.0286) |
AUROC: 0.575 [0.559, 0.591] | Nagelkerke's Pseudo-R²: 0.0139 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.871, 2.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 |
| PPM001134 | PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.093 [1.034, 1.155] β: 0.0888 (0.0282) |
AUROC: 0.525 [0.509, 0.54] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.04, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 |
| PPM001136 | PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.144 [1.084, 1.208] β: 0.135 (0.0278) |
AUROC: 0.521 [0.506, 0.536] | Nagelkerke's Pseudo-R²: 0.00396 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.65, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 |
| PPM001137 | PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.663 [1.57, 1.761] β: 0.508 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.53, 5.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 |
| PPM001139 | PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.661 [1.568, 1.759] β: 0.507 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0489 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.79 [2.68, 5.35] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 |
| PPM001140 | PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 |
| PPM001141 | PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.633 [1.541, 1.729] β: 0.49 (0.0293) |
AUROC: 0.63 [0.615, 0.646] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.95 [2.79, 5.58] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 |
| PPM001143 | PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.634 [1.542, 1.732] β: 0.491 (0.0296) |
AUROC: 0.628 [0.612, 0.644] | Nagelkerke's Pseudo-R²: 0.0457 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.86, 5.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 |
| PPM001144 | PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.528 [1.485, 1.572] β: 0.424 (0.0144) |
AUROC: 0.615 [0.608, 0.623] | Nagelkerke's Pseudo-R²: 0.0314 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.05 [2.55, 3.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 |
| PPM001146 | PGS000461 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.491 [1.395, 1.593] β: 0.4 (0.0338) |
AUROC: 0.599 [0.579, 0.618] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0974 Odds Ratio (OR, top 1% vs. Rest): 3.51 [2.29, 5.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 |
| PPM001147 | PGS000462 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.324 [1.288, 1.361] β: 0.28 (0.014) |
AUROC: 0.573 [0.564, 0.58] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.13 [1.74, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608 |
| PPM001261 | PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.489 [1.39, 1.596] β: 0.398 (0.0353) |
AUROC: 0.607 [0.589, 0.627] | Nagelkerke's Pseudo-R²: 0.0358 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 |
| PPM001149 | PGS000464 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.332 [1.296, 1.369] β: 0.287 (0.014) |
AUROC: 0.575 [0.567, 0.582] | Nagelkerke's Pseudo-R²: 0.0147 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.19 [1.79, 2.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608 |
| PPM001150 | PGS000465 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.457 [1.365, 1.554] β: 0.376 (0.033) |
AUROC: 0.589 [0.57, 0.61] | Nagelkerke's Pseudo-R²: 0.0282 Brier score: 0.0976 Odds Ratio (OR, top 1% vs. Rest): 4.54 [3.07, 6.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608 |
| PPM001152 | PGS000467 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608) |
PSS000545| European Ancestry| 8,473 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.43 [1.341, 1.525] β: 0.358 (0.0328) |
AUROC: 0.583 [0.564, 0.603] | Nagelkerke's Pseudo-R²: 0.0261 Brier score: 0.0978 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.49, 5.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608 |
| PPM001153 | PGS000468 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608) |
PSS000569| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.334 [1.299, 1.371] β: 0.288 (0.0138) |
AUROC: 0.571 [0.563, 0.579] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 1.93 [1.56, 2.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608 |
| PPM001155 | PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.308 [1.208, 1.417] β: 0.269 (0.0407) |
AUROC: 0.557 [0.531, 0.582] | Nagelkerke's Pseudo-R²: 0.0154 Brier score: 0.093 Odds Ratio (OR, top 1% vs. Rest): 2.45 [1.34, 4.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 |
| PPM001156 | PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.401 [1.297, 1.513] β: 0.337 (0.0393) |
AUROC: 0.569 [0.541, 0.595] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0923 Odds Ratio (OR, top 1% vs. Rest): 3.77 [2.24, 6.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 |
| PPM001158 | PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.315 [1.238, 1.398] β: 0.274 (0.0311) |
AUROC: 0.576 [0.56, 0.592] | Nagelkerke's Pseudo-R²: 0.0167 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.981, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608 |
| PPM001159 | PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.26, 1.422] β: 0.291 (0.0308) |
AUROC: 0.58 [0.563, 0.597] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.54 [0.924, 2.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608 |
| PPM001161 | PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.365 [1.286, 1.45] β: 0.311 (0.0305) |
AUROC: 0.585 [0.569, 0.603] | Nagelkerke's Pseudo-R²: 0.0218 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.97 [1.24, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608 |
| PPM001162 | PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.259, 1.421] β: 0.291 (0.0308) |
AUROC: 0.581 [0.564, 0.597] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.38, 3.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608 |
| PPM001164 | PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.438 [1.354, 1.528] β: 0.364 (0.0308) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.03 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.37 [1.54, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608 |
| PPM001167 | PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.358 [1.279, 1.442] β: 0.306 (0.0306) |
AUROC: 0.584 [0.568, 0.601] | Nagelkerke's Pseudo-R²: 0.0212 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.43 [0.853, 2.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PT_MGI_20200608 |
| PPM001168 | PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.404 [1.322, 1.491] β: 0.339 (0.0308) |
AUROC: 0.595 [0.579, 0.61] | Nagelkerke's Pseudo-R²: 0.0264 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.3, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608 |
| PPM001170 | PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608 |
| PPM001171 | PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.4 [1.363, 1.437] β: 0.336 (0.0134) |
AUROC: 0.592 [0.585, 0.6] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [2.16, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608 |
| PPM001173 | PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.426 [1.389, 1.464] β: 0.355 (0.0134) |
AUROC: 0.598 [0.59, 0.605] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608 |
| PPM001174 | PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.254 [1.181, 1.33] β: 0.226 (0.0304) |
AUROC: 0.564 [0.547, 0.58] | Nagelkerke's Pseudo-R²: 0.012 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.05, 2.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001176 | PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.326 [1.246, 1.411] β: 0.282 (0.0317) |
AUROC: 0.578 [0.56, 0.594] | Nagelkerke's Pseudo-R²: 0.0179 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.13, 2.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
| PPM001177 | PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.296, 1.366] β: 0.286 (0.0134) |
AUROC: 0.579 [0.572, 0.586] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.95, 2.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
| PPM001179 | PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.248 [1.216, 1.28] β: 0.221 (0.0132) |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
| PPM001180 | PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.297 [1.221, 1.377] β: 0.26 (0.0307) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.87 [1.16, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
| PPM001182 | PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.521 [1.43, 1.619] β: 0.42 (0.0316) |
AUROC: 0.614 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.51, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
| PPM001183 | PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.553] β: 0.414 (0.0133) |
AUROC: 0.613 [0.606, 0.621] | Nagelkerke's Pseudo-R²: 0.0311 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 2.71 [2.28, 3.23] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
| PPM001184 | PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.708 [1.601, 1.822] β: 0.535 (0.033) |
AUROC: 0.643 [0.627, 0.658] | Nagelkerke's Pseudo-R²: 0.0603 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 3.71 [2.52, 5.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
| PPM001186 | PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.564 [1.469, 1.665] β: 0.447 (0.0318) |
AUROC: 0.621 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0438 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.77, 4.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
| PPM001187 | PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.555 [1.514, 1.596] β: 0.441 (0.0135) |
AUROC: 0.621 [0.614, 0.628] | Nagelkerke's Pseudo-R²: 0.0347 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.36 [2.87, 3.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001189 | PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.621 [1.578, 1.665] β: 0.483 (0.0136) |
AUROC: 0.631 [0.624, 0.638] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.86 [3.31, 4.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001190 | PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.584 [1.488, 1.686] β: 0.46 (0.0318) |
AUROC: 0.625 [0.609, 0.641] | Nagelkerke's Pseudo-R²: 0.0462 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.24, 4.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001215 | PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.441 [1.404, 1.479] β: 0.365 (0.0132) |
AUROC: 0.6 [0.593, 0.608] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.92 [2.47, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
| PPM001217 | PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.49 [1.451, 1.529] β: 0.399 (0.0134) |
AUROC: 0.608 [0.601, 0.615] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 3.0 [2.54, 3.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
| PPM001218 | PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.489 [1.401, 1.583] β: 0.398 (0.0312) |
AUROC: 0.607 [0.591, 0.623] | Nagelkerke's Pseudo-R²: 0.0354 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.63, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
| PPM001220 | PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.568 [1.473, 1.668] β: 0.45 (0.0317) |
AUROC: 0.622 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0443 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 3.43 [2.32, 5.05] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
| PPM001221 | PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.571 [1.53, 1.614] β: 0.452 (0.0136) |
AUROC: 0.623 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.036 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.54 [3.02, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001224 | PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.585 [1.489, 1.687] β: 0.46 (0.0319) |
AUROC: 0.624 [0.607, 0.641] | Nagelkerke's Pseudo-R²: 0.0464 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.49 [1.61, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001226 | PGS000541 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608) |
PSS000571| European Ancestry| 6,987 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of uterus | OR: 1.311 [1.209, 1.422] β: 0.271 (0.0415) |
AUROC: 0.576 [0.553, 0.6] | Nagelkerke's Pseudo-R²: 0.0133 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.12 [1.17, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608 |
| PPM001227 | PGS000542 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608) |
PSS000571| European Ancestry| 6,987 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of uterus | OR: 1.302 [1.2, 1.413] β: 0.264 (0.0416) |
AUROC: 0.572 [0.549, 0.596] | Nagelkerke's Pseudo-R²: 0.0126 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.6 [1.5, 4.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608 |
| PPM001229 | PGS000544 (PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_P_5e-08_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.12 [1.021, 1.23] β: 0.114 (0.0475) |
AUROC: 0.532 [0.506, 0.559] | Nagelkerke's Pseudo-R²: 0.00239 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 0.923 [0.347, 2.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_P_5e-08_UKB_20200608 |
| PPM001230 | PGS000545 (PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_PT_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.12 [1.021, 1.23] β: 0.114 (0.0475) |
AUROC: 0.532 [0.506, 0.559] | Nagelkerke's Pseudo-R²: 0.00239 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 0.923 [0.347, 2.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_GWAS-Catalog-r2019-05-03-X184.11_PT_UKB_20200608 |
| PPM001232 | PGS000547 (PRSWEB_PHECODE184.11_Phelan-EPOC_P_5e-08_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.156 [1.051, 1.27] β: 0.145 (0.0482) |
AUROC: 0.544 [0.517, 0.573] | Nagelkerke's Pseudo-R²: 0.00379 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 0.922 [0.347, 2.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-EPOC_P_5e-08_UKB_20200608 |
| PPM001233 | PGS000548 (PRSWEB_PHECODE184.11_Phelan-EPOC_LASSOSUM_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.132 [1.03, 1.244] β: 0.124 (0.0483) |
AUROC: 0.538 [0.512, 0.565] | Nagelkerke's Pseudo-R²: 0.00277 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.13 [0.463, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-EPOC_LASSOSUM_UKB_20200608 |
| PPM001235 | PGS000550 (PRSWEB_PHECODE184.11_Phelan-IEOC_PRS-CS_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.286 [1.169, 1.414] β: 0.251 (0.0485) |
AUROC: 0.568 [0.542, 0.595] | Nagelkerke's Pseudo-R²: 0.0113 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.838, 3.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-IEOC_PRS-CS_UKB_20200608 |
| PPM001236 | PGS000551 (PRSWEB_PHECODE184.11_Phelan-IEOC_PT_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.234 [1.125, 1.354] β: 0.21 (0.0473) |
AUROC: 0.558 [0.53, 0.586] | Nagelkerke's Pseudo-R²: 0.00819 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.55 [0.71, 3.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-IEOC_PT_UKB_20200608 |
| PPM001238 | PGS000553 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_P_5e-08_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.188 [1.079, 1.308] β: 0.172 (0.0491) |
AUROC: 0.556 [0.53, 0.584] | Nagelkerke's Pseudo-R²: 0.00531 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.839, 3.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-LSASBOC_P_5e-08_UKB_20200608 |
| PPM001239 | PGS000554 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_PRS-CS_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.11 [1.009, 1.221] β: 0.104 (0.0486) |
AUROC: 0.522 [0.491, 0.548] | Nagelkerke's Pseudo-R²: 0.00193 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 3.92 [2.27, 6.79] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-LSASBOC_PRS-CS_UKB_20200608 |
| PPM001241 | PGS000556 (PRSWEB_PHECODE184.11_Phelan-LSASBOC_LASSOSUM_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.122 [1.022, 1.233] β: 0.116 (0.0478) |
AUROC: 0.516 [0.489, 0.544] | Nagelkerke's Pseudo-R²: 0.00242 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.4 [1.24, 4.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-LSASBOC_LASSOSUM_UKB_20200608 |
| PPM001242 | PGS000557 (PRSWEB_PHECODE184.11_Phelan-OCCC_PRS-CS_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.149 [1.045, 1.262] β: 0.139 (0.048) |
AUROC: 0.534 [0.508, 0.562] | Nagelkerke's Pseudo-R²: 0.00348 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.55 [0.71, 3.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-OCCC_PRS-CS_UKB_20200608 |
| PPM001244 | PGS000559 (PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_MGI_20200608) |
PSS000550| European Ancestry| 1,904 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.183 [1.015, 1.378] β: 0.168 (0.078) |
AUROC: 0.554 [0.509, 0.597] | Nagelkerke's Pseudo-R²: 0.00516 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 0.784 [0.142, 4.32] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_MGI_20200608 |
| PPM001245 | PGS000560 (PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.233 [1.125, 1.352] β: 0.21 (0.047) |
AUROC: 0.552 [0.523, 0.581] | Nagelkerke's Pseudo-R²: 0.00819 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.76 [0.839, 3.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_P_5e-08_UKB_20200608 |
| PPM001247 | PGS000562 (PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.209 [1.099, 1.329] β: 0.19 (0.0484) |
AUROC: 0.552 [0.526, 0.58] | Nagelkerke's Pseudo-R²: 0.00646 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.55 [0.708, 3.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_PRS-CS_UKB_20200608 |
| PPM001248 | PGS000563 (PRSWEB_PHECODE184.11_Phelan-SIOC_PT_UKB_20200608) |
PSS000572| European Ancestry| 5,196 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of ovary | OR: 1.192 [1.086, 1.308] β: 0.175 (0.0476) |
AUROC: 0.547 [0.52, 0.574] | Brier score: 0.0826 Nagelkerke's Pseudo-R²: 0.00564 Odds Ratio (OR, top 1% vs. Rest): 0.511 [0.142, 1.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184.11_Phelan-SIOC_PT_UKB_20200608 |
| PPM001250 | PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.434 [1.336, 1.54] β: 0.361 (0.0363) |
AUROC: 0.596 [0.579, 0.615] | Nagelkerke's Pseudo-R²: 0.0271 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 |
| PPM001251 | PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.393 [1.3, 1.493] β: 0.332 (0.0352) |
AUROC: 0.591 [0.573, 0.609] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.152 Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 |
| PPM001252 | PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.505 [1.404, 1.613] β: 0.409 (0.0354) |
AUROC: 0.608 [0.59, 0.628] | Nagelkerke's Pseudo-R²: 0.0379 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 |
| PPM001253 | PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.426 [1.332, 1.527] β: 0.355 (0.035) |
AUROC: 0.595 [0.577, 0.614] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 |
| PPM001254 | PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.643 [1.531, 1.763] β: 0.496 (0.036) |
AUROC: 0.63 [0.613, 0.648] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 |
| PPM001256 | PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.67 [1.555, 1.793] β: 0.513 (0.0363) |
AUROC: 0.634 [0.617, 0.653] | Nagelkerke's Pseudo-R²: 0.0583 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 |
| PPM001263 | PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.746 [1.681, 1.813] β: 0.557 (0.0192) |
AUROC: 0.653 [0.642, 0.662] | Nagelkerke's Pseudo-R²: 0.0565 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 |
| PPM001265 | PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.748 [1.684, 1.815] β: 0.559 (0.0192) |
AUROC: 0.653 [0.643, 0.663] | Nagelkerke's Pseudo-R²: 0.0568 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 |
| PPM001266 | PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.79 [1.665, 1.925] β: 0.582 (0.0371) |
AUROC: 0.651 [0.634, 0.669] | Nagelkerke's Pseudo-R²: 0.071 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 |
| PPM001268 | PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.929 [1.79, 2.078] β: 0.657 (0.038) |
AUROC: 0.668 [0.651, 0.687] | Nagelkerke's Pseudo-R²: 0.0874 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 |
| PPM001269 | PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.173 [2.087, 2.263] β: 0.776 (0.0206) |
AUROC: 0.705 [0.695, 0.715] | Nagelkerke's Pseudo-R²: 0.1 Brier score: 0.0791 Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 |
| PPM001271 | PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.018 [1.94, 2.1] β: 0.702 (0.0203) |
AUROC: 0.687 [0.678, 0.698] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.0799 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 |
| PPM001272 | PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.906 [1.771, 2.051] β: 0.645 (0.0375) |
AUROC: 0.665 [0.647, 0.684] | Nagelkerke's Pseudo-R²: 0.0861 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 |
| PPM001274 | PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.63 [1.52, 1.748] β: 0.489 (0.0356) |
AUROC: 0.63 [0.612, 0.648] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 |
| PPM001275 | PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.516 [1.415, 1.624] β: 0.416 (0.0353) |
AUROC: 0.614 [0.595, 0.633] | Nagelkerke's Pseudo-R²: 0.0395 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 |
| PPM001277 | PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.648] β: 0.43 (0.0357) |
AUROC: 0.616 [0.598, 0.635] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 |
| PPM001278 | PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.193 [1.002, 1.419] β: 0.176 (0.0887) |
AUROC: 0.551 [0.5, 0.6] | Nagelkerke's Pseudo-R²: 0.00553 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.01 [0.177, 5.76] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 |
| PPM001280 | PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.713 [1.33, 2.206] β: 0.538 (0.129) |
AUROC: 0.658 [0.594, 0.719] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.0838 Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.535, 13.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 |
| PPM001281 | PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.68 [1.28, 2.206] β: 0.519 (0.139) |
AUROC: 0.649 [0.586, 0.714] | Nagelkerke's Pseudo-R²: 0.0475 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.49 [0.816, 14.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 |
| PPM001283 | PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.639 [1.263, 2.126] β: 0.494 (0.133) |
AUROC: 0.648 [0.581, 0.712] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.85 [0.942, 15.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 |
| PPM001284 | PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.628 [1.281, 2.069] β: 0.487 (0.122) |
AUROC: 0.637 [0.568, 0.703] | Nagelkerke's Pseudo-R²: 0.0473 Brier score: 0.0844 Odds Ratio (OR, top 1% vs. Rest): 4.35 [1.08, 17.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 |
| PPM001286 | PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.438 [1.132, 1.827] β: 0.363 (0.122) |
AUROC: 0.598 [0.526, 0.672] | Nagelkerke's Pseudo-R²: 0.0258 Brier score: 0.085 |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 |
| PPM001287 | PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.055 [1.692, 2.496] β: 0.72 (0.0993) |
AUROC: 0.698 [0.656, 0.74] | Nagelkerke's Pseudo-R²: 0.0839 Brier score: 0.0795 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 |
| PPM001289 | PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.106 [1.729, 2.565] β: 0.745 (0.101) |
AUROC: 0.703 [0.659, 0.745] | Brier score: 0.0793 Nagelkerke's Pseudo-R²: 0.0882 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 |
| PPM001290 | PGS000605 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608) |
PSS000575| European Ancestry| 5,818 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of kidney, except pelvis | OR: 1.154 [1.062, 1.254] β: 0.143 (0.0426) |
AUROC: 0.517 [0.492, 0.54] | Nagelkerke's Pseudo-R²: 0.00398 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.13, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_P_5e-08_UKB_20200608 |
| PPM001291 | PGS000606 (PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608) |
PSS000575| European Ancestry| 5,818 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of kidney, except pelvis | OR: 1.154 [1.062, 1.254] β: 0.143 (0.0426) |
AUROC: 0.517 [0.492, 0.54] | Nagelkerke's Pseudo-R²: 0.00398 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.13, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.11_GWAS-Catalog-r2019-05-03-X189.11_PT_UKB_20200608 |
| PPM001293 | PGS000608 (PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.084 [1.006, 1.167] β: 0.0803 (0.0377) |
AUROC: 0.521 [0.499, 0.541] | Nagelkerke's Pseudo-R²: 0.00124 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.832, 2.83] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_C3-BLADDER_PRS-CS_MGI_20200608 |
| PPM001295 | PGS000610 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.292 [1.201, 1.391] β: 0.256 (0.0375) |
AUROC: 0.572 [0.55, 0.594] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0917 Odds Ratio (OR, top 1% vs. Rest): 1.47 [0.779, 2.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_MGI_20200608 |
| PPM001298 | PGS000613 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.301 [1.227, 1.379] β: 0.263 (0.0299) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0125 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.91 [1.99, 4.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_PT_UKB_20200608 |
| PPM001299 | PGS000614 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.087 [1.01, 1.171] β: 0.0836 (0.0377) |
AUROC: 0.525 [0.503, 0.547] | Nagelkerke's Pseudo-R²: 0.00135 Brier score: 0.0922 Odds Ratio (OR, top 1% vs. Rest): 0.675 [0.28, 1.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_PRS-CS_MGI_20200608 |
| PPM001301 | PGS000616 (PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608) |
PSS000555| European Ancestry| 7,622 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.138 [1.057, 1.225] β: 0.129 (0.0376) |
AUROC: 0.538 [0.517, 0.557] | Nagelkerke's Pseudo-R²: 0.00345 Brier score: 0.0921 Odds Ratio (OR, top 1% vs. Rest): 0.983 [0.459, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_UKBB-SAIGE-HRC-X189.2_LASSOSUM_MGI_20200608 |
| PPM001302 | PGS000617 (PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608) |
PSS000556| European Ancestry| 672 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of eye | OR: 1.339 [1.033, 1.736] β: 0.292 (0.132) |
AUROC: 0.586 [0.508, 0.658] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 4.74 [1.2, 18.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE190_20001-1030_PRS-CS_MGI_20200608 |
| PPM001262 | PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.756 [1.634, 1.886] β: 0.563 (0.0366) |
AUROC: 0.646 [0.627, 0.665] | Nagelkerke's Pseudo-R²: 0.0678 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 |
| PPM001303 | PGS000618 (PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608) |
PSS000578| European Ancestry| 3,110 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain and nervous system | OR: 1.569 [1.399, 1.759] β: 0.45 (0.0585) |
AUROC: 0.623 [0.592, 0.656] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 3.64 [1.76, 7.53] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.1_GWAS-Catalog-r2019-05-03-X191.1_P_5e-08_UKB_20200608 |
| PPM001305 | PGS000620 (PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.195 [1.045, 1.367] β: 0.179 (0.0686) |
AUROC: 0.546 [0.504, 0.587] | Nagelkerke's Pseudo-R²: 0.00561 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.453, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_C71_LASSOSUM_MGI_20200608 |
| PPM001306 | PGS000621 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.159 [1.015, 1.324] β: 0.148 (0.068) |
AUROC: 0.54 [0.503, 0.579] | Nagelkerke's Pseudo-R²: 0.00394 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.02 [0.271, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_P_5e-08_MGI_20200608 |
| PPM001308 | PGS000623 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608) |
PSS000557| European Ancestry| 2,563 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.153 [1.01, 1.316] β: 0.142 (0.0676) |
AUROC: 0.538 [0.501, 0.577] | Nagelkerke's Pseudo-R²: 0.00369 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 0.602 [0.113, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_MGI_20200608 |
| PPM001309 | PGS000624 (PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608) |
PSS000577| European Ancestry| 3,020 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of brain | OR: 1.515 [1.344, 1.708] β: 0.415 (0.0611) |
AUROC: 0.606 [0.568, 0.642] | Nagelkerke's Pseudo-R²: 0.0326 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.15 [2.04, 8.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE191.11_GWAS-Catalog-r2019-05-03-X191.11_PT_UKB_20200608 |
| PPM001311 | PGS000626 (PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.161 [1.048, 1.285] β: 0.149 (0.052) |
AUROC: 0.529 [0.496, 0.559] | Nagelkerke's Pseudo-R²: 0.0041 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.18, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_20001-1065_PT_MGI_20200608 |
| PPM001312 | PGS000627 (PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.27 [1.148, 1.405] β: 0.239 (0.0515) |
AUROC: 0.56 [0.53, 0.59] | Nagelkerke's Pseudo-R²: 0.0107 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.17, 4.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_PT_MGI_20200608 |
| PPM001313 | PGS000628 (PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.276 [1.155, 1.41] β: 0.244 (0.0509) |
AUROC: 0.565 [0.535, 0.595] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0823 Odds Ratio (OR, top 1% vs. Rest): 1.91 [0.861, 4.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_C3-THYROID-GLAND_LASSOSUM_MGI_20200608 |
| PPM001315 | PGS000630 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.598 [1.439, 1.775] β: 0.469 (0.0536) |
AUROC: 0.626 [0.597, 0.655] | Nagelkerke's Pseudo-R²: 0.0393 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.53 [1.87, 6.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_MGI_20200608 |
| PPM001316 | PGS000631 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.651 [1.41, 1.934] β: 0.501 (0.0806) |
AUROC: 0.636 [0.589, 0.682] | Nagelkerke's Pseudo-R²: 0.0478 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.4 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_P_5e-08_UKB_20200608 |
| PPM001318 | PGS000633 (PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608) |
PSS000579| European Ancestry| 1,778 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.609 [1.38, 1.876] β: 0.476 (0.0783) |
AUROC: 0.628 [0.582, 0.675] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0804 Odds Ratio (OR, top 1% vs. Rest): 4.41 [1.81, 10.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_GWAS-Catalog-r2019-05-03-X193_PT_UKB_20200608 |
| PPM001319 | PGS000634 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.119 [1.008, 1.241] β: 0.112 (0.053) |
AUROC: 0.535 [0.504, 0.567] | Nagelkerke's Pseudo-R²: 0.00228 Brier score: 0.0827 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.562, 3.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_PRS-CS_MGI_20200608 |
| PPM001321 | PGS000636 (PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608) |
PSS000558| European Ancestry| 4,270 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Thyroid cancer | OR: 1.385 [1.254, 1.529] β: 0.325 (0.0507) |
AUROC: 0.578 [0.548, 0.607] | Nagelkerke's Pseudo-R²: 0.0205 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 3.21 [1.67, 6.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE193_UKBB-SAIGE-HRC-X193_LASSOSUM_MGI_20200608 |
| PPM001322 | PGS000637 (PRSWEB_PHECODE201_20001-1052_PRS-CS_MGI_20200608) |
PSS000559| European Ancestry| 775 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Hodgkin's disease | OR: 1.3 [1.023, 1.651] β: 0.262 (0.122) |
AUROC: 0.574 [0.501, 0.642] | Nagelkerke's Pseudo-R²: 0.013 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.67 [0.264, 10.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE201_20001-1052_PRS-CS_MGI_20200608 |
| PPM001324 | PGS000639 (PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_PT_MGI_20200608) |
PSS000559| European Ancestry| 775 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Hodgkin's disease | OR: 1.476 [1.154, 1.889] β: 0.39 (0.126) |
AUROC: 0.62 [0.559, 0.688] | Nagelkerke's Pseudo-R²: 0.0276 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.572, 12.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE201_GWAS-Catalog-r2019-05-03-X201_PT_MGI_20200608 |
| PPM001325 | PGS000640 (PRSWEB_PHECODE201_UKBB-SAIGE-HRC-X201_LASSOSUM_MGI_20200608) |
PSS000559| European Ancestry| 775 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Hodgkin's disease | OR: 1.292 [1.011, 1.651] β: 0.256 (0.125) |
AUROC: 0.569 [0.501, 0.634] | Nagelkerke's Pseudo-R²: 0.0109 Brier score: 0.0828 Odds Ratio (OR, top 1% vs. Rest): 1.64 [0.261, 10.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE201_UKBB-SAIGE-HRC-X201_LASSOSUM_MGI_20200608 |
| PPM001326 | PGS000641 (PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_P_5e-08_UKB_20200608) |
PSS000580| European Ancestry| 9,952 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Non-Hodgkins lymphoma | OR: 1.211 [1.133, 1.294] β: 0.191 (0.034) |
AUROC: 0.541 [0.521, 0.561] | Nagelkerke's Pseudo-R²: 0.00682 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.24, 3.4] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_P_5e-08_UKB_20200608 |
| PPM001328 | PGS000643 (PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_PRS-CS_MGI_20200608) |
PSS000560| European Ancestry| 3,256 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Nodular lymphoma | OR: 1.133 [1.005, 1.277] β: 0.125 (0.061) |
AUROC: 0.532 [0.497, 0.568] | Nagelkerke's Pseudo-R²: 0.00282 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 2.49 [1.1, 5.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_PRS-CS_MGI_20200608 |
| PPM001329 | PGS000644 (PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_LASSOSUM_MGI_20200608) |
PSS000560| European Ancestry| 3,256 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Nodular lymphoma | OR: 1.149 [1.021, 1.294] β: 0.139 (0.0606) |
AUROC: 0.538 [0.504, 0.573] | Nagelkerke's Pseudo-R²: 0.00349 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.538, 4.05] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE202.21_C-FOLLICULAR-LYMPHOMA_LASSOSUM_MGI_20200608 |
| PPM001331 | PGS000646 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_MGI_20200608) |
PSS000561| European Ancestry| 756 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 2.104 [1.628, 2.718] β: 0.744 (0.131) |
AUROC: 0.696 [0.628, 0.765] | Nagelkerke's Pseudo-R²: 0.0973 Brier score: 0.0779 Odds Ratio (OR, top 1% vs. Rest): 11.3 [3.76, 33.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_MGI_20200608 |
| PPM001332 | PGS000647 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_UKB_20200608) |
PSS000581| European Ancestry| 2,758 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 1.874 [1.639, 2.144] β: 0.628 (0.0685) |
AUROC: 0.675 [0.64, 0.707] | Nagelkerke's Pseudo-R²: 0.0689 Brier score: 0.0795 Odds Ratio (OR, top 1% vs. Rest): 4.11 [1.97, 8.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_P_5e-08_UKB_20200608 |
| PPM001334 | PGS000649 (PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_UKB_20200608) |
PSS000581| European Ancestry| 2,758 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 1.85 [1.619, 2.114] β: 0.615 (0.0681) |
AUROC: 0.672 [0.637, 0.703] | Nagelkerke's Pseudo-R²: 0.0665 Brier score: 0.0796 Odds Ratio (OR, top 1% vs. Rest): 2.52 [1.04, 6.08] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_GWAS-Catalog-r2019-05-03-X204.12_PT_UKB_20200608 |
| PPM001335 | PGS000650 (PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_PT_MGI_20200608) |
PSS000561| European Ancestry| 756 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Lymphoid leukemia, chronic | OR: 1.368 [1.097, 1.705] β: 0.313 (0.113) |
AUROC: 0.577 [0.511, 0.645] | Nagelkerke's Pseudo-R²: 0.0205 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.0 [0.308, 13.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.12_UKBB-SAIGE-HRC-X204.12_PT_MGI_20200608 |
| PPM001338 | PGS000653 (PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608) |
PSS000582| European Ancestry| 2,738 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Multiple myeloma | OR: 1.327 [1.165, 1.511] β: 0.283 (0.0663) |
AUROC: 0.577 [0.537, 0.617] | Nagelkerke's Pseudo-R²: 0.0145 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.2 [0.855, 5.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE204.4_GWAS-Catalog-r2019-05-03-X204.4_P_5e-08_UKB_20200608 |
| PPM001191 | PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.567 [1.526, 1.609] β: 0.449 (0.0134) |
AUROC: 0.622 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.0361 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.69 [3.16, 4.31] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
| PPM001193 | PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.756 [1.709, 1.804] β: 0.563 (0.0138) |
AUROC: 0.652 [0.645, 0.658] | Nagelkerke's Pseudo-R²: 0.0548 Brier score: 0.0805 Odds Ratio (OR, top 1% vs. Rest): 4.38 [3.79, 5.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
| PPM001194 | PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.643 [1.542, 1.75] β: 0.496 (0.0323) |
AUROC: 0.635 [0.618, 0.651] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.88, 4.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608 |
| PPM001196 | PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.7 [1.594, 1.813] β: 0.53 (0.0328) |
AUROC: 0.641 [0.625, 0.656] | Nagelkerke's Pseudo-R²: 0.0592 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 2.48 [1.63, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
| PPM001197 | PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.699 [1.654, 1.746] β: 0.53 (0.0138) |
AUROC: 0.643 [0.637, 0.65] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.0807 Odds Ratio (OR, top 1% vs. Rest): 4.02 [3.46, 4.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
| PPM001199 | PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.391 [1.309, 1.478] β: 0.33 (0.031) |
AUROC: 0.59 [0.573, 0.607] | Nagelkerke's Pseudo-R²: 0.0248 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.12, 2.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608 |
| PPM001259 | PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.506 [1.406, 1.614] β: 0.41 (0.0352) |
AUROC: 0.612 [0.593, 0.63] | Nagelkerke's Pseudo-R²: 0.039 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 |
| PPM001200 | PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.453 [1.367, 1.544] β: 0.374 (0.0311) |
AUROC: 0.605 [0.588, 0.621] | Nagelkerke's Pseudo-R²: 0.0307 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.31, 3.32] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608 |
| PPM001202 | PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.229 [1.157, 1.305] β: 0.206 (0.0306) |
AUROC: 0.55 [0.533, 0.566] | Nagelkerke's Pseudo-R²: 0.0097 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.17, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
| PPM001203 | PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.18 [1.15, 1.21] β: 0.165 (0.0131) |
AUROC: 0.542 [0.534, 0.55] | Nagelkerke's Pseudo-R²: 0.00504 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.49 [1.2, 1.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
| PPM001051 | PGS000366 (PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608) |
PSS000537| European Ancestry| 2,064 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of esophagus | OR: 1.24 [1.067, 1.441] β: 0.215 (0.0766) |
AUROC: 0.564 [0.522, 0.605] | Nagelkerke's Pseudo-R²: 0.00839 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.28 [0.332, 4.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE150_UKBB-SAIGE-HRC-X150_PRS-CS_MGI_20200608 |
| PPM001115 | PGS000430 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.219 [1.151, 1.292] β: 0.198 (0.0296) |
AUROC: 0.555 [0.54, 0.573] | Nagelkerke's Pseudo-R²: 0.00721 Brier score: 0.0965 Odds Ratio (OR, top 1% vs. Rest): 1.64 [1.01, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608 |
| PPM001185 | PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.674 [1.63, 1.719] β: 0.515 (0.0137) |
AUROC: 0.64 [0.634, 0.647] | Nagelkerke's Pseudo-R²: 0.0463 Brier score: 0.0809 Odds Ratio (OR, top 1% vs. Rest): 3.64 [3.12, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
| PPM001255 | PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.572 [1.465, 1.687] β: 0.452 (0.0359) |
AUROC: 0.622 [0.604, 0.639] | Nagelkerke's Pseudo-R²: 0.0453 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 |
| PPM001327 | PGS000642 (PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_PT_UKB_20200608) |
PSS000580| European Ancestry| 9,952 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Non-Hodgkins lymphoma | OR: 1.239 [1.16, 1.324] β: 0.214 (0.0337) |
AUROC: 0.547 [0.527, 0.566] | Nagelkerke's Pseudo-R²: 0.0087 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.24, 3.4] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE202.2_GWAS-Catalog-r2019-05-03-X202.2_PT_UKB_20200608 |
| PPM001059 | PGS000374 (PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608) |
PSS000540| European Ancestry| 6,633 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | OR: 1.091 [1.004, 1.185] β: 0.0872 (0.0423) |
AUROC: 0.517 [0.493, 0.541] | Nagelkerke's Pseudo-R²: 0.00134 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.88 [0.99, 3.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153_UKBB-SAIGE-HRC-X153_PT_MGI_20200608 |
| PPM001069 | PGS000384 (PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608) |
PSS000539| European Ancestry| 3,557 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of rectum, rectosigmoid junction, and anus | OR: 1.122 [1.001, 1.257] β: 0.115 (0.058) |
AUROC: 0.531 [0.495, 0.563] | Nagelkerke's Pseudo-R²: 0.00251 Brier score: 0.0829 Odds Ratio (OR, top 1% vs. Rest): 1.02 [0.334, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE153.3_C3-RECTUM_PRS-CS_MGI_20200608 |
| PPM001094 | PGS000409 (PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.192 [1.126, 1.263] β: 0.176 (0.0292) |
AUROC: 0.547 [0.531, 0.563] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0966 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.25, 3.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608 |
| PPM001097 | PGS000412 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608) |
PSS000543| European Ancestry| 11,974 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.414 [1.338, 1.495] β: 0.347 (0.0282) |
AUROC: 0.585 [0.569, 0.6] | Nagelkerke's Pseudo-R²: 0.0236 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 3.26 [2.26, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608 |
| PPM001129 | PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.399 [1.341, 1.46] β: 0.336 (0.0216) |
AUROC: 0.59 [0.578, 0.601] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.5 [2.63, 4.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 |
| PPM001165 | PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.253, 1.412] β: 0.285 (0.0304) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0186 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.91 [1.2, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608 |
| PPM001223 | PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.448 [1.411, 1.486] β: 0.37 (0.0132) |
AUROC: 0.602 [0.594, 0.609] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.78 [2.34, 3.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608 |
| PPM001296 | PGS000611 (PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608) |
PSS000576| European Ancestry| 13,530 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of bladder | OR: 1.284 [1.211, 1.361] β: 0.25 (0.0298) |
AUROC: 0.567 [0.551, 0.584] | Nagelkerke's Pseudo-R²: 0.0114 Brier score: 0.0821 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.79, 3.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE189.2_GWAS-Catalog-r2019-05-03-X189.2_P_5e-08_UKB_20200608 |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000554 | PheCode:187; ICD9CM:186.0, 186.9, 187.1, 187.2, 187.3, 187.4, 187.5, 187.6, 187.7, 187.8, 187.9, 233.5, 233.6, 236.4, 236.5, 236.6, V10.45, V10.47, V10.48, V10.49; ICD10CM:C60, C60.0, C60.1, C60.2, C60.8, C60.9, C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92, C63, C63.0, C63.00, C63.01, C63.02, C63.1, C63.10, C63.11, C63.12, C63.2, C63.7, C63.8, C63.9, D07.4, D07.6, D07.60, D07.61, D07.69, D40, D40.0, D40.1, D40.10, D40.11, D40.12, D40.8, D40.9 | — | [
|
— | European | — | MGI | — |
| PSS000555 | PheCode:189.2; ICD9CM:188.0, 188.1, 188.2, 188.3, 188.4, 188.5, 188.6, 188.7, 188.8, 188.9, 233.7, 236.7, 239.4, V10.51; ICD10CM:C67, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4, D49.4 | — | [
|
— | European | — | MGI | — |
| PSS000556 | PheCode:190; ICD9CM:190.0, 190.1, 190.2, 190.3, 190.4, 190.5, 190.6, 190.7, 190.8, 190.9, 234.0, V10.84; ICD10CM:C69, C69.0, C69.00, C69.01, C69.02, C69.1, C69.10, C69.11, C69.12, C69.2, C69.20, C69.21, C69.22, C69.3, C69.30, C69.31, C69.32, C69.4, C69.40, C69.41, C69.42, C69.5, C69.50, C69.51, C69.52, C69.6, C69.60, C69.61, C69.62, C69.8, C69.80, C69.81, C69.82, C69.9, C69.90, C69.91, C69.92, D09.2, D09.20, D09.21, D09.22 | — | [
|
— | European | — | MGI | — |
| PSS000557 | PheCode:191.11; ICD9CM:191.0, 191.1, 191.2, 191.3, 191.4, 191.5, 191.6, 191.7, 191.8, 191.9, V10.85; ICD10CM:C71, C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9 | — | [
|
— | European | — | MGI | — |
| PSS000558 | PheCode:193; ICD9CM:193, V10.87; ICD10CM:C73 | — | [
|
— | European | — | MGI | — |
| PSS000559 | PheCode:201; ICD9CM:201.00, 201.01, 201.02, 201.03, 201.04, 201.05, 201.06, 201.07, 201.08, 201.10, 201.11, 201.12, 201.13, 201.14, 201.15, 201.16, 201.17, 201.18, 201.20, 201.21, 201.22, 201.23, 201.24, 201.25, 201.26, 201.27, 201.28, 201.40, 201.41, 201.42, 201.43, 201.44, 201.45, 201.46, 201.47, 201.48, 201.50, 201.51, 201.52, 201.53, 201.54, 201.55, 201.56, 201.57, 201.58, 201.60, 201.61, 201.62, 201.63, 201.64, 201.65, 201.66, 201.67, 201.68, 201.70, 201.71, 201.72, 201.73, 201.74, 201.75, 201.76, 201.77, 201.78, 201.90, 201.91, 201.92, 201.93, 201.94, 201.95, 201.96, 201.97, 201.98, V10.72; ICD10CM:C81, C81.0, C81.00, C81.01, C81.02, C81.03, C81.04, C81.05, C81.06, C81.07, C81.08, C81.09, C81.1, C81.10, C81.11, C81.12, C81.13, C81.14, C81.15, C81.16, C81.17, C81.18, C81.19, C81.2, C81.20, C81.21, C81.22, C81.23, C81.24, C81.25, C81.26, C81.27, C81.28, C81.29, C81.3, C81.30, C81.31, C81.32, C81.33, C81.34, C81.35, C81.36, C81.37, C81.38, C81.39, C81.4, C81.40, C81.41, C81.42, C81.43, C81.44, C81.45, C81.46, C81.47, C81.48, C81.49, C81.7, C81.70, C81.71, C81.72, C81.73, C81.74, C81.75, C81.76, C81.77, C81.78, C81.79, C81.9, C81.90, C81.91, C81.92, C81.93, C81.94, C81.95, C81.96, C81.97, C81.98, C81.99 | — | [
|
— | European | — | MGI | — |
| PSS000560 | PheCode:202.21; ICD9CM:202.00, 202.01, 202.02, 202.03, 202.04, 202.05, 202.06, 202.07, 202.08; ICD10CM:C82, C82.0, C82.00, C82.01, C82.02, C82.03, C82.04, C82.05, C82.06, C82.07, C82.08, C82.09, C82.1, C82.10, C82.11, C82.12, C82.13, C82.14, C82.15, C82.16, C82.17, C82.18, C82.19, C82.2, C82.20, C82.21, C82.22, C82.23, C82.24, C82.25, C82.26, C82.27, C82.28, C82.29, C82.3, C82.30, C82.31, C82.32, C82.33, C82.34, C82.35, C82.36, C82.37, C82.38, C82.39, C82.4, C82.40, C82.41, C82.42, C82.43, C82.44, C82.45, C82.46, C82.47, C82.48, C82.49, C82.5, C82.50, C82.51, C82.52, C82.53, C82.54, C82.55, C82.56, C82.57, C82.58, C82.59, C82.6, C82.60, C82.61, C82.62, C82.63, C82.64, C82.65, C82.66, C82.67, C82.68, C82.69, C82.8, C82.80, C82.81, C82.82, C82.83, C82.84, C82.85, C82.86, C82.87, C82.88, C82.89, C82.9, C82.90, C82.91, C82.92, C82.93, C82.94, C82.95, C82.96, C82.97, C82.98, C82.99 | — | [
|
— | European | — | MGI | — |
| PSS000561 | PheCode:204.12; ICD9CM:204.10, 204.11, 204.12; ICD10CM:C91.1, C91.10, C91.11, C91.12 | — | [
|
— | European | — | MGI | — |
| PSS000562 | PheCode:204.1; ICD9CM:204.00, 204.01, 204.02, 204.10, 204.11, 204.12, 204.20, 204.21, 204.22, 204.80, 204.81, 204.82, 204.90, 204.91, 204.92, V10.61; ICD10CM:C91, C91.0, C91.00, C91.01, C91.02, C91.1, C91.10, C91.11, C91.12, C91.3, C91.30, C91.31, C91.32, C91.4, C91.40, C91.41, C91.42, C91.5, C91.50, C91.51, C91.52, C91.6, C91.60, C91.61, C91.62, C91.9, C91.90, C91.91, C91.92, C91.A, C91.A0, C91.A1, C91.A2, C91.Z, C91.Z0, C91.Z1, C91.Z2 | — | [
|
— | European | — | MGI | — |
| PSS000563 | PheCode:204.4; ICD9CM:203.00, 203.01, 203.02, 203.80, 203.81, 203.82; ICD10CM:C88.2, C88.3, C88.9, C90.0, C90.00, C90.01, C90.02, C90.2, C90.20, C90.21, C90.22, C90.30, C90.31, C90.32 | — | [
|
— | European | — | MGI | — |
| PSS000564 | PheCode:153; ICD9:154.8; ICD10:C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20, C21.0, C21.1, C21.8, C26.0, D01.0, D01.1, D01.2, D01.3 | — | [
|
— | European | — | UKB | — |
| PSS000565 | PheCode:157; ICD9:157, 157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9; ICD10:C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9 | — | [
|
— | European | — | UKB | — |
| PSS000566 | PheCode:165.1; ICD9:162, 162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 231.2; ICD10:C33, C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, D02.2 | — | [
|
— | European | — | UKB | — |
| PSS000567 | PheCode:172.1; ICD9:-; ICD10:C43.0, C43.1, C43.2, C43.3, C43.4, C43.5, C43.6, C43.7, C43.8, C43.9, D03.0, D03.1, D03.2, D03.3, D03.4, D03.5, D03.6, D03.7, D03.8, D03.9 | — | [
|
— | European | — | UKB | — |
| PSS000568 | PheCode:172.21; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
| PSS000569 | PheCode:172.22; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
| PSS000570 | PheCode:174.1; ICD9:233.0; ICD10:C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9, D05.1, D05.7, D05.9, Z85.3 | — | [
|
— | European | — | UKB | — |
| PSS000571 | PheCode:182; ICD9:179, 182, 182.0, 182.1, 182.8, 233.2; ICD10:C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55, D07.0 | — | [
|
— | European | — | UKB | — |
| PSS000572 | PheCode:184.11; ICD9:183.0; ICD10:C56 | — | [
|
— | European | — | UKB | — |
| PSS000573 | PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5 | — | [
|
— | European | — | UKB | — |
| PSS000574 | PheCode:187.2; ICD9:186, 186.0, 186.9; ICD10:C62.0, C62.1, C62.9 | — | [
|
— | European | — | UKB | — |
| PSS000575 | PheCode:189.11; ICD9:189.0; ICD10:C64 | — | [
|
— | European | — | UKB | — |
| PSS000576 | PheCode:189.2; ICD9:233.7, 236.7, 239.4; ICD10:C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0, D41.4 | — | [
|
— | European | — | UKB | — |
| PSS000577 | PheCode:191.11; ICD9:191, 191.0, 191.1, 191.2, 191.3, 191.4, 191.5, 191.6, 191.7, 191.8, 191.9; ICD10:C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9 | — | [
|
— | European | — | UKB | — |
| PSS000578 | PheCode:191.1; ICD9:192, 192.0, 192.1, 192.2, 192.3, 192.8, 192.9; ICD10:C70.0, C70.1, C70.9, C71.0, C71.1, C71.2, C71.3, C71.4, C71.5, C71.6, C71.7, C71.8, C71.9, C72.0, C72.1, C72.2, C72.3, C72.4, C72.5, C72.8, C72.9 | — | [
|
— | European | — | UKB | — |
| PSS000579 | PheCode:193; ICD9:193; ICD10:C73 | — | [
|
— | European | — | UKB | — |
| PSS000580 | PheCode:202.2; ICD9:200, 200.2, 200.8, 202.1, 202.2, 202.8, 202.9; ICD10:B21.1, C82.0, C82.1, C82.2, C82.7, C82.9, C83.0, C83.1, C83.2, C83.3, C83.4, C83.5, C83.6, C83.7, C83.8, C83.9, C84.0, C84.1, C84.2, C84.3, C84.4, C84.5, C85.0, C85.1, C85.7, C85.9, C96.7, C96.9, L41.2 | — | [
|
— | European | — | UKB | — |
| PSS000581 | PheCode:204.12; ICD9:204.1; ICD10:C91.1 | — | [
|
— | European | — | UKB | — |
| PSS000582 | PheCode:204.4; ICD9:203, 203.0, 203.8; ICD10:C88.1, C88.3, C88.9, C90.0, C90.2 | — | [
|
— | European | — | UKB | — |
| PSS000533 | Any Cancer PheCode | — | [
|
— | European | — | MGI | — |
| PSS000534 | PheCode:145.2; ICD9CM:141.0, 141.1, 141.2, 141.3, 141.4, 141.5, 141.6, 141.8, 141.9, V10.01; ICD10CM:C01, C02, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9 | — | [
|
— | European | — | MGI | — |
| PSS000535 | PheCode:145; ICD9CM:140.0, 140.1, 140.3, 140.4, 140.5, 140.6, 140.8, 140.9, 141.0, 141.1, 141.2, 141.3, 141.4, 141.5, 141.6, 141.8, 141.9, 142.0, 142.1, 142.2, 142.8, 142.9, 143.0, 143.1, 143.8, 143.9, 144.0, 144.1, 144.8, 144.9, 145.0, 145.1, 145.2, 145.3, 145.4, 145.5, 145.6, 145.8, 145.9, 230.0, V10.01; ICD10CM:C00, C00.0, C00.1, C00.2, C00.3, C00.4, C00.5, C00.6, C00.8, C00.9, C01, C02, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9, C03, C03.0, C03.1, C03.9, C04, C04.0, C04.1, C04.8, C04.9, C05, C05.0, C05.1, C05.2, C05.8, C05.9, C06, C06.0, C06.1, C06.2, C06.8, C06.80, C06.89, C06.9, C07, C08, C08.0, C08.1, C08.9, D00.0, D00.00, D00.01, D00.02, D00.03, D00.04, D00.05, D00.06, D00.07, D00.08 | — | [
|
— | European | — | MGI | — |
| PSS000536 | PheCode:149.4; ICD9CM:161.0, 161.1, 161.2, 161.3, 161.8, 161.9, 231.0, V10.21; ICD10CM:C32, C32.0, C32.1, C32.2, C32.3, C32.8, C32.9, D02.0 | — | [
|
— | European | — | MGI | — |
| PSS000537 | PheCode:150; ICD9CM:150.0, 150.1, 150.2, 150.3, 150.4, 150.5, 150.8, 150.9, 230.1, V10.03; ICD10CM:C15, C15.3, C15.4, C15.5, C15.8, C15.9, D00.1 | — | [
|
— | European | — | MGI | — |
| PSS000538 | PheCode:153.2; ICD9CM:153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9, 159.0, 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 230.3, V10.05; ICD10CM:C18, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C26.0, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.029, D01.0 | — | [
|
— | European | — | MGI | — |
| PSS000539 | PheCode:153.3; ICD9CM:154.0, 154.1, 154.2, 154.3, 209.17, 230.4, 230.5, 230.6, 796.70, 796.71, 796.72, 796.73, 796.74, 796.76, V10.06; ICD10CM:C19, C20, C21.0, C21.1, C7A.026, D01.1, D01.2, D01.3, R85.610, R85.611, R85.612, R85.613, R85.614, R85.619 | — | [
|
— | European | — | MGI | — |
| PSS000540 | PheCode:153; ICD9CM:153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9, 154.0, 154.1, 154.2, 154.3, 154.8, 159.0, 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 209.17, 230.3, 230.4, 230.5, 230.6, 796.70, 796.71, 796.72, 796.73, 796.74, 796.76, V10.05, V10.06; ICD10CM:C18, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20, C21.0, C21.1, C21.2, C21.8, C26.0, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, D01.0, D01.1, D01.2, D01.3, R85.610, R85.611, R85.612, R85.613, R85.614, R85.619 | — | [
|
— | European | — | MGI | — |
| PSS000541 | PheCode:165.1; ICD9CM:162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 209.21, 231.2, V10.11; ICD10CM:C33, C34, C34.0, C34.00, C34.01, C34.02, C34.1, C34.10, C34.11, C34.12, C34.2, C34.3, C34.30, C34.31, C34.32, C34.8, C34.80, C34.81, C34.82, C34.9, C34.90, C34.91, C34.92, C7A.090, D02.2, D02.20, D02.21, D02.22 | — | [
|
— | European | — | MGI | — |
| PSS000542 | PheCode:165; ICD9CM:162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 163.0, 163.1, 163.8, 163.9, 165.0, 165.8, 165.9, 209.21, 231.1, 231.2, 231.8, 231.9, V10.11, V10.12, V10.20, V10.29; ICD10CM:C33, C34, C34.0, C34.00, C34.01, C34.02, C34.1, C34.10, C34.11, C34.12, C34.2, C34.3, C34.30, C34.31, C34.32, C34.8, C34.80, C34.81, C34.82, C34.9, C34.90, C34.91, C34.92, C38.4, C39, C39.0, C39.9, C45.0, C7A.090, D02.1, D02.2, D02.20, D02.21, D02.22, D02.3, D02.4 | — | [
|
— | European | — | MGI | — |
| PSS000543 | PheCode:172.1; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, V10.82; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9 | — | [
|
— | European | — | MGI | — |
| PSS000544 | PheCode:172.21; ICD9CM:173.01, 173.11, 173.21, 173.31, 173.41, 173.51, 173.61, 173.71, 173.81, 173.91; ICD10CM:C44.01, C44.111, C44.112, C44.119, C44.211, C44.212, C44.219, C44.310, C44.311, C44.319, C44.41, C44.510, C44.511, C44.519, C44.611, C44.612, C44.619, C44.711, C44.712, C44.719, C44.81, C44.91 | — | [
|
— | European | — | MGI | — |
| PSS000545 | PheCode:172.22; ICD9CM:173.02, 173.12, 173.22, 173.32, 173.42, 173.52, 173.62, 173.72, 173.82, 173.92; ICD10CM:C44.02, C44.121, C44.122, C44.129, C44.221, C44.222, C44.229, C44.320, C44.321, C44.329, C44.42, C44.520, C44.521, C44.529, C44.621, C44.622, C44.629, C44.721, C44.722, C44.729, C44.82, C44.92 | — | [
|
— | European | — | MGI | — |
| PSS000546 | PheCode:172.2; ICD9CM:173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, V10.83; ICD10CM:C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9 | — | [
|
— | European | — | MGI | — |
| PSS000547 | PheCode:172.3; ICD9CM:232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9; ICD10CM:D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000548 | PheCode:172; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, 173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, 232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9, V10.82, V10.83; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9, D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
| PSS000549 | PheCode:174.1; ICD9CM:174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233.0, V10.3; ICD10CM:C50, C50.0, C50.01, C50.011, C50.012, C50.019, C50.02, C50.021, C50.022, C50.029, C50.1, C50.11, C50.111, C50.112, C50.119, C50.12, C50.121, C50.122, C50.129, C50.2, C50.21, C50.211, C50.212, C50.219, C50.22, C50.221, C50.222, C50.229, C50.3, C50.31, C50.311, C50.312, C50.319, C50.32, C50.321, C50.322, C50.329, C50.4, C50.41, C50.411, C50.412, C50.419, C50.42, C50.421, C50.422, C50.429, C50.5, C50.51, C50.511, C50.512, C50.519, C50.52, C50.521, C50.522, C50.529, C50.6, C50.61, C50.611, C50.612, C50.619, C50.62, C50.621, C50.622, C50.629, C50.8, C50.81, C50.811, C50.812, C50.819, C50.82, C50.821, C50.822, C50.829, C50.9, C50.91, C50.911, C50.912, C50.919, C50.92, C50.921, C50.922, C50.929, D05, D05.0, D05.00, D05.01, D05.02, D05.1, D05.10, D05.11, D05.12, D05.8, D05.80, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92 | — | [
|
— | European | — | MGI | — |
| PSS000550 | PheCode:184.11; ICD9CM:183.0, V10.43; ICD10CM:C56, C56.1, C56.2, C56.9 | — | [
|
— | European | — | MGI | — |
| PSS000551 | PheCode:184; ICD9CM:181, 183.0, 183.2, 183.3, 183.4, 183.5, 183.8, 183.9, 184.0, 184.1, 184.2, 184.3, 184.4, 184.8, 184.9, 233.30, 233.31, 233.32, 233.39, 236.0, 236.1, 236.2, 236.3, V10.40, V10.43, V10.44; ICD10CM:C51, C51.0, C51.1, C51.2, C51.8, C51.9, C52, C56, C56.1, C56.2, C56.9, C57, C57.0, C57.00, C57.01, C57.02, C57.1, C57.10, C57.11, C57.12, C57.2, C57.20, C57.21, C57.22, C57.3, C57.4, C57.7, C57.8, C57.9, C58, D07.1, D07.2, D07.3, D07.30, D07.39, D39, D39.0, D39.1, D39.10, D39.11, D39.12, D39.2, D39.8, D39.9, N90.3 | — | [
|
— | European | — | MGI | — |
| PSS000552 | PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5 | — | [
|
— | European | — | MGI | — |
| PSS000553 | PheCode:187.2; ICD9CM:186.0, 186.9, V10.47; ICD10CM:C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92 | — | [
|
— | European | — | MGI | — |